<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005580" GROUP_ID="SCHIZ" ID="463703032710390352" MERGED_FROM="" MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old title: Antipsychotic medication for elderly people with schizophrenia.&lt;br&gt;Old title: Antipsychotic medication for elderly people with schizophrenia&lt;br&gt;Old title: Antipsychotic medication for elderly people with schizophrenia.&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 13:59:35 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="rgm" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Antipsychotic medication for elderly people with schizophrenia</TITLE>
<CONTACT MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="0AE0077D82E26AA2004A583DE200F90F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><LAST_NAME>Marriott</LAST_NAME><POSITION>Consultant in Old Age Psychiatry</POSITION><EMAIL_1>rmarriott@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>South Yorkshire Mental Health Trust</DEPARTMENT><ORGANISATION>Calder Unit, Fieldhead Hospital</ORGANISATION><ADDRESS_1>Ouchthorpe Lane</ADDRESS_1><CITY>Wakefireld</CITY><ZIP>WF1 3SP</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01924 328631</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="0AE0077D82E26AA2004A583DE200F90F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><LAST_NAME>Marriott</LAST_NAME><POSITION>Consultant in Old Age Psychiatry</POSITION><EMAIL_1>rmarriott@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>South Yorkshire Mental Health Trust</DEPARTMENT><ORGANISATION>Calder Unit, Fieldhead Hospital</ORGANISATION><ADDRESS_1>Ouchthorpe Lane</ADDRESS_1><CITY>Wakefireld</CITY><ZIP>WF1 3SP</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01924 328631</PHONE_1></ADDRESS></PERSON><PERSON ID="0AE5DCA782E26AA2004A583DC104C3E7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Wendy</FIRST_NAME><LAST_NAME>Neil</LAST_NAME><POSITION>Specialist Registrar in Old Age Psychiatry</POSITION><EMAIL_1>wendy.neil@leesmh.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Aire Court Community Unit</DEPARTMENT><ORGANISATION>NHS</ORGANISATION><ADDRESS_1>Lingwell Grove</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS10 4BH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0113 277 4861</PHONE_1><FAX_1>0113 277 4895</FAX_1></ADDRESS></PERSON><PERSON ID="0AE3C44682E26AA2004A583DD6164E58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Susie</FIRST_NAME><LAST_NAME>Waddingham</LAST_NAME><POSITION>Specialist Registrar in Old Age Psychiatry</POSITION><EMAIL_1>susiewaddingham@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Millside Community Unit</DEPARTMENT><ORGANISATION>NHS</ORGANISATION><ADDRESS_1>Mill Pond Lane</ADDRESS_1><ADDRESS_2>Meanwood</ADDRESS_2><CITY>Leeds</CITY><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 0113 295 5412</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-21 13:52:01 +0100" MODIFIED_BY="Bethany York" NOTES="&lt;p&gt;Minor update: 10/11/05&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 13:52:01 +0100" NOTES_MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="4" MONTH="9" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="9" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="10" YEAR="2005"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="11" MONTH="11" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:40:46 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="2" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="4" MONTH="9" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Leeds Mental Health Teaching NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-02 16:30:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-02 16:25:54 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-02 16:25:54 +0100" MODIFIED_BY="[Empty name]">Antipsychotic medication for elderly people with schizophrenia</TITLE>
<SUMMARY_BODY>
<P>Since the early 1950's the mainstay of treatment for schizophrenia has been drugs such as haloperidol and chlorpromazine. Although effective in controlling voices and fixed, false beliefs, these drugs are reported as having potentially disabling adverse effects such as tremor, stiffness and slowing of movement. The newer generation of drugs are reputed to be freer from these problems. This is particularly important for older people, who are more likely to experience adverse effects. Most manufacturers recommend prescription of reduced doses in the elderly.</P>
<P>This review examines trials of these drugs for the treatment of elderly people with schizophrenia. We found three small, short trials. These did not have much information that was usable and we really could not draw any firm conclusions, except that such studies are possible and more are needed as a matter of urgency.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>A large and growing number of older people across the world suffer from schizophrenia. Recommendations for their treatment are largely based on data extrapolated from studies of the use of antipsychotic medications in younger populations. In addition most manufacturers of such medications recommend prescription of reduced doses to the elderly. The evidence base for these assumptions is unclear and raises obvious questions regarding the appropriateness of such prescribing practice.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To find and assimilate good evidence of the effects of antipsychotic medication for treatment of schizophrenia in people over 65 years of age.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Schizophrenia Group's Register (May 2003). We inspected references of all included studies for further trials and contacted relevant pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All clinical randomised trials evaluating antipsychotic drugs for schizophrenia and schizophrenia-like psychoses in older people.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We extracted data independently. For homogenous dichotomous data, the random effects, relative risk (RR), and 95% confidence interval (CI) and, where appropriate, the numbers needed to treat (NNT) were calculated on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two hundred and fifty two elderly people with schizophrenia participated in three relevant randomised controlled studies. We were unable to extract usable data on quality of life, satisfaction, service use, or economic outcomes. One small study (n=18) compared thioridazine with remoxipride (RR leaving the study early 1.0 CI 0.07 to 13.6). A second study (n=175) compared risperidone with olanzapine. Global state 'not improved/worse' was not significantly different between treatments (n= 171, RR 1.26 CI 0.8 to 1.9); mental state PANSS total endpoint scores were also equivocal (n=171, RR 0.98 CI 0.76 to 1.26) as were all cognitive function tests. The third study (subset n=59) compared olanzapine with haloperidol and mental state change scores (BPRS WMD -3.60 CI -10.8 to 3.6; PANSS WMD -6.00 CI -18.3 to 6.3) were equivocal.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Antipsychotics may be widely used in the treatment of elderly people with schizophrenia, however, based on this systematic review, there are little robust data available to guide the clinician with respect to the most appropriate drug to prescribe. Clearly reported large short, medium and long-term randomised controlled trials with participants, interventions and primary outcomes that are familiar to those wishing to help elderly people with schizophrenia are long overdue.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-02 16:30:26 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>The number of older people in communities throughout the world is rising. In the most recent UK census (2001) the proportion of people over 60 years of age surpassed the figures for the under 16's for the first time (21% versus 20%). There are now 9.4 million people over the age of 65 in the UK, a 51% increase since 1961, and the figure is projected to rise to 13 million by 2025. These trends are even more marked in those over 85 years who now number 1.1 million, three times more than in 1961 (<LINK REF="REF-UK-ONS-2003" TYPE="REFERENCE">UK ONS 2003</LINK>).<BR/> <BR/>Worldwide the situation is similar. The most recent UN statistics reveal that in the year 2000 there were 606 million people over 60 years, and by 2050 the figure is expected to be nearly 2 billion. The figures for the over 80s are expected to rise over five times from 69 million to 379 million in 2050. In most developed countries, as in Britain, the proportion of people over 60 years is about 20% but is expected to rise to 33% by 2050 with two people over 60 to every child. In less developed countries the rise will be even more marked (from 8% to 20% by 2050) (<LINK REF="REF-UN-Popin-2003" TYPE="REFERENCE">UN Popin 2003</LINK>).</P>
<P>Schizophrenia is a common mental disorder with a lifetime risk of between 7.0 and 13.0 per 1000 (<LINK REF="REF-Jablensky-1986" TYPE="REFERENCE">Jablensky 1986</LINK>, <LINK REF="REF-Regier-1988" TYPE="REFERENCE">Regier 1988</LINK>, <LINK REF="REF-Kessler-1994" TYPE="REFERENCE">Kessler 1994</LINK>). The prognosis for patients presenting with a first episode of schizophrenia is unclear, however various studies suggest that while up to a third make a good recovery, the remainder suffer from persistent symptoms or a relapsing and remitting course requiring on-going treatment (<LINK REF="REF-Bleuler-1974" TYPE="REFERENCE">Bleuler 1974</LINK>, <LINK REF="REF-Ciompi-1980" TYPE="REFERENCE">Ciompi 1980</LINK>, <LINK REF="REF-Huber-1975" TYPE="REFERENCE">Huber 1975</LINK>). It is estimated that 0.1-1.0% of the over 65 population has schizophrenia (<LINK REF="REF-Sajatovic-2000" TYPE="REFERENCE">Sajatovic 2000</LINK>), including up to 12% of all nursing home residents (<LINK REF="REF-Tariot-1993" TYPE="REFERENCE">Tariot 1993</LINK>).</P>
<P>Although the life course of schizophrenia into later adulthood is not well studied, it is generally recognised that, whereas psychotic symptoms tend to remit with time, negative symptoms, such as social withdrawal and emotional apathy, increase in frequency and intensity with advancing age (<LINK REF="REF-Sajatovic-2000" TYPE="REFERENCE">Sajatovic 2000</LINK>). Ten percent of all first admissions over 60 years of age to psychiatric hospitals are diagnosed with late onset paranoid disorders (<LINK REF="REF-Naguib-1995" TYPE="REFERENCE">Naguib 1995</LINK>). Late onset schizophrenia (illness onset after 40 years of age) and very late onset schizophrenia (illness onset after 60 years of age) tend to follow a relatively benign course, with predominant positive symptoms and fewer negative symptoms, although relapse is frequent, often as a consequence of medication non-compliance (<LINK REF="REF-Howard-2000" TYPE="REFERENCE">Howard 2000</LINK>). Antipsychotic treatment of people with late and very late onset schizophrenia is the focus of a companion review (<LINK REF="REF-Arunpongpaisal-2003" TYPE="REFERENCE">Arunpongpaisal 2003</LINK>) and will not be covered by this one. This review includes the larger group of people who have grown older with a diagnosis of schizophrenia having been made before the age of 65. </P>
<P>With regard to treatment of schizophrenia, most manufacturers of antipsychotic medication recommend prescription of reduced doses to the elderly. There are logical reasons why an older person might metabolise these medications less rapidly and might be more susceptible to adverse effects. However the use of antipsychotic medications in older people with schizophrenia is largely based on data extrapolated from studies of these agents in younger populations (<LINK REF="REF-Katz-1999" TYPE="REFERENCE">Katz 1999</LINK>, <LINK REF="REF-Frenchman-1997" TYPE="REFERENCE">Frenchman 1997</LINK>, <LINK REF="REF-Devanand-1998" TYPE="REFERENCE">Devanand 1998</LINK>). It is unclear how these studies relate to older patients, particularly those who have been on antipsychotic medication for many years. A number of open studies have been conducted with elderly participants with schizophrenia and suggest that the atypical antipsychotics may be of benefit (<LINK REF="REF-Czobor-1995" TYPE="REFERENCE">Czobor 1995</LINK>, <LINK REF="REF-Davidson-2000" TYPE="REFERENCE">Davidson 2000</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To estimate the effects of antipsychotic medication for treatment of schizophrenia in people over 65 years of age (this being the standard recognised division between working age and older adults in the UK). </P>
<P>It is also proposed to investigate whether low doses of antipsychotic medications have different effects when compared with standard or high doses for the treatment of positive and negative symptoms of schizophrenia in older patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-02 16:30:26 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-02 16:29:43 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials. Where a trial was described as 'double-blind' but it was implied that the study was randomised, these trials were included in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then they were included in the final analysis. If there was a substantive difference only clearly randomised trials were utilised and the results of the sensitivity analysis described in the text. Quasi-randomised studies, such as those allocating by using alternate days of the week, were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Older people, or cohorts of adults of whom at least 80% were over 65 years of age, resident in any setting, with a diagnosis of schizophrenia as defined in individual studies of schizophrenia or other schizophrenia-like psychosis (including delusional disorder, schizophreniform psychosis, paraphrenia and schizoaffective disorder). Studies including other diagnoses that may also present with psychotic phenomena (e.g. bi-polar affective disorder and organic causes of altered mental state e.g. delirium and dementia) were excluded unless 80% or more of the participants had a diagnosis of schizophrenia or other schizophrenia-like psychosis. If a study reported that some, but not over 80% of patients were over 65 years, then we attempted to contact the authors in order to obtain separate data relating to those patients who were over 65 years.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Atypical antipsychotic drugs<BR/>All these drugs share the common characteristics of reduced risk of acute and chronic movement disorders compared with typical antipsychotic agents (<LINK REF="REF-Kerwin-1994" TYPE="REFERENCE">Kerwin 1994</LINK>). We included in this category both the 'new' serotonin-dopamine antagonists (SDA's); clozapine, iloperidone, olanzapine, quetiapine, risperidone, ziprasidone, zotepine and aripiprazole, a dopamine partial agonist, together with older agents with no significant action on the serotonin receptor (e.g. amisulpiride, sulpiride) at any dose and mode or pattern of administration.</P>
<P>2. Typical antipsychotic drugs<BR/>For the purposes of this review these are any antipsychotic drugs exerting their effect through blockade of D2 receptors, without the specific characteristics described above (<LINK REF="REF-Seeman-1987" TYPE="REFERENCE">Seeman 1987</LINK>). This includes benperidone, chlorpromazine, flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone, oxypertine, pericyazine, perphenazine, pimozide, prochlorperazine, promazine, thioridazine, thiothixene, trifluoperazine and zuclopenthixol, at any dose and mode or pattern of administration.</P>
<P>If there were cases where a study reported the effects of a drug confirmed as being an antipsychotic through reference to the standard pharmacopoeia (<LINK REF="REF-Martindale-1999" TYPE="REFERENCE">Martindale 1999</LINK>), but difficult to categorise it as being either typical or atypical, a psychopharmacologist, blinded to the study details, was contacted to aid allocation of category.</P>
<P>3. Placebo</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-02 16:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>As schizophrenia is often a life-long illness, and anti-psychotic drugs are used as an ongoing treatment, we grouped outcomes according to time periods: acute treatment (less than 6 weeks), short term (less than 3 months), medium term (3-6 months), and long term (more than 6 months).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-02 16:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Global state</P>
<P>1.1 Relapse</P>
<P>2. Mental state<BR/>2.1 No clinically important change in general mental state</P>
<P>3. Adverse effects<BR/>3.1 No clinically important general adverse effects</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-02 16:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Death - suicide and natural causes</P>
<P>2. Global state<BR/>2.1 Time to relapse<BR/>2.2 No clinically important change in global state<BR/>2.3 Not any change in global state<BR/>2.4 Average endpoint global state score<BR/>2.5 Average change in global state scores</P>
<P>3. Service outcomes<BR/>3.1 Hospitalisation<BR/>3.2 Time to hospitalisation</P>
<P>4. Mental state<BR/>4.1 Not any change in general mental state<BR/>4.2 Average endpoint general mental state score<BR/>4.3 Average change in general mental state scores<BR/>4.4 No clinically important change in specific symptoms<BR/>4.5 Not any change in specific symptoms<BR/>4.6 Average endpoint specific symptom score<BR/>4.7 Average change in specific symptom scores</P>
<P>5. Leaving the study early<BR/>5.1 For specific reasons<BR/>5.2 For general reasons</P>
<P>6. General functioning<BR/>6.1 No clinically important change in general functioning<BR/>6.2 Not any change in general functioning<BR/>6.3 Average endpoint general functioning score<BR/>6.4 Average change in general functioning scores<BR/>6.5 No clinically important change in specific aspects of functioning, such as social or life skills<BR/>6.6 Not any change in specific aspects of functioning, such as social or life skills<BR/>6.7 Average endpoint specific aspects of functioning, such as social or life skills<BR/>6.8 Average change in specific aspects of functioning, such as social or life skills</P>
<P>7. Behaviour<BR/>7.1 No clinically important change in general behaviour<BR/>7.2 Not any change in general behaviour<BR/>7.3 Average endpoint general behaviour score<BR/>7.4 Average change in general behaviour scores<BR/>7.5 No clinically important change in specific aspects of behaviour<BR/>7.6 Not any change in specific aspects of behaviour<BR/>7.7 Average endpoint specific aspects of behaviour<BR/>7.8 Average change in specific aspects of behaviour</P>
<P>8. Adverse effects<BR/>8.1 Not any general adverse effects<BR/>8.2 Average endpoint general adverse effect score<BR/>8.3 Average change in general adverse effect scores<BR/>8.4 No clinically important change in specific adverse effects<BR/>8.5 Not any change in specific adverse effects<BR/>8.6 Average endpoint specific adverse effects<BR/>8.7 Average change in specific adverse effects</P>
<P>9. Engagement with services<BR/>9.1 No clinically important engagement<BR/>9.2 Not any engagement<BR/>9.3 Average endpoint engagement score<BR/>9.4 Average change in engagement scores</P>
<P>10. Satisfaction with treatment<BR/>10.1 Recipient of care not satisfied with treatment<BR/>10.2 Recipient of care average satisfaction score<BR/>10.3 Recipient of care average change in satisfaction scores<BR/>10.4 Carer not satisfied with treatment<BR/>10.5 Carer average satisfaction score<BR/>10.6 Carer average change in satisfaction scores</P>
<P>11. Quality of life<BR/>11.1 No clinically important change in quality of life<BR/>11.2 Not any change in quality of life<BR/>11.3 Average endpoint quality of life score<BR/>11.4 Average change in quality of life scores<BR/>11.5 No clinically important change in specific aspects of quality of life<BR/>11.6 Not any change in specific aspects of quality of life<BR/>11.7 Average endpoint specific aspects of quality of life<BR/>11.8 Average change in specific aspects of quality of life</P>
<P>12. Economic outcomes<BR/>12.1 Direct costs<BR/>12.2 Indirect costs</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-02 16:30:26 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-02 16:30:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Electronic searching<BR/>We searched the Cochrane Schizophrenia Groups trials register (April 2003) using the phrase: [(((elderly* or *elderly* in abstract terms or title) or (old* or * old *) in title in abstract, index terms or title) or (aged* in index terms) of REFERENCE) or (elderly in participants of STUDY))].</P>
<P>This register is compiled by up-to-date methodical searches of BIOSIS, The Cochrane Library CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, and is supplemented with hand searching of relevant journals and numerous conference proceedings (see Group Module).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-02 16:30:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. References<BR/>We inspected the references of all the identified studies for further trials.</P>
<P>2. Personal contact<BR/>We contacted authors of included trials for additional studies.</P>
<P>3. Pharmaceutical industry<BR/>We contacted relevant pharmaceutical companies for information about additional studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of studies <BR/>We independently selected study citations identified from the trial search in order to assess their relevance for inclusion according to the selection criteria. Each study citation was inspected by RM and/or WN and/or SW. If studies were identified as relevant or if there was any disagreement about inclusion, we obtained the full article. In cases of dispute we inspected the full article and attempted to reach an agreement through discussion. If this failed, we were assisted by the third reviewer to try to resolve any doubts. If agreement could still not be reached, we contacted the authors for more information and the article was allocated to the list of 'those awaiting assessment' until additional information could be acquired to resolve the situation.</P>
<P>2. Assessment of quality of methodology<BR/>We assessed the methodological quality of each study independently (RM and/or WN and/or SW). The criteria we used were based upon those described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Trials were included if they were allocated to category A or B with regards to randomisation (Cochrane Handbook criteria: A=randomisation and concealment, B=just randomisation, C=improper randomisation; A &amp; B suggest a low-moderate risk of bias). Where disagreement arose, we attempted to resolve it through discussion; if doubts still remained, we discussed these with the third reviewer; if we were still unable to reach consensus the authors were contacted for more information and the article was allocated to the list of those awaiting assessment.</P>
<P>3. Data management</P>
<P>3.1 Data extraction <BR/>We (RM and/or WN and/or SW) independently extracted data from the selected trials. In cases of dispute, we discussed any doubts in order to reach agreement. If this failed the third reviewer was involved to assist but if there were still outstanding issues a decision was made to contact the authors for more information and the article was allocated to the list of those awaiting assessment. In this case, data were not entered unless additional information became available.</P>
<P>3.2 Intention to treat analysis<BR/>We excluded data from outcomes of studies where more than 50% of participants in any group were lost to follow up. In outcomes with less than 50% dropout rate, we assumed people leaving early to have had the negative outcome, except for the event of death. We analysed the impact of including outcomes with high attrition rates (25-50%) in a sensitivity analysis. If inclusion of data from this latter group did result in a substantive change in the estimate of effect, their data were not added to trials with less attrition, but presented separately.</P>
<P>4. Data synthesis<BR/>In the assessment of outcome, two types of data were used - dichotomous and continuous.</P>
<P>4.1 Dichotomous data<BR/>Dichotomous data were used wherever possible. If a continuous measure had been used and the trialist had identified an appropriate cut-off point, we used this. In other cases, where continuous data could be made binary, we agreed a suitable cut-off point, with one of us blind to the data. We calculated a standard estimation of the random effects risk ratio (RR) and its 95% confidence interval (CI). The random effects model enables differences between studies to be taken into account. Where possible we estimated the number needed to treat (NNT) or the number needed to harm (NNH) taking into account the risk of an event in the control group (<LINK REF="REF-Cates-2005" TYPE="REFERENCE">Cates 2005</LINK>). We carried out an intention-to-treat analysis. In the calculation, all people lost to follow-up were assumed to have had a poor outcome.</P>
<P>4.2 Continuous data</P>
<P>4.2.1 Skewed data<BR/>The statistics used in meta-analysis were designed for use with parametric data. However, the outcome data from trials of anti-psychotic drugs are frequently skewed. To allow for this potential problem, standards were applied to all data before inclusion: (a) standard deviations (SDs) and means were reported in the paper (or were obtainable from the authors), (b) for data with finite limits, such as endpoint scale data, the standard deviation (SD) when multiplied by two was less than the mean (otherwise the mean was unlikely to be an appropriate measure of the centre of distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>)). (c) if a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale), it is difficult to tell whether data are non-normally distributed (skewed) or not. Skewed data from studies of less than 200 participants would have been entered in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and would have been entered into a synthesis. If these standards were not met, we reported these data separately. </P>
<P>4.2.2 Summary statistic<BR/>For continuous outcomes, we estimated a weighted mean difference (WMD) between groups. Again, we used a random effects model.</P>
<P>4.2.3 Endpoint versus change data<BR/>Where possible we presented endpoint data and if both endpoint and change data were available for the same outcomes then we only reported the former. In cases of change data (end-point minus baseline) the situation is more difficult. Without individual patient data it is impossible to know if the data are skewed. Since RevMan meta-analyses of continuous data are based on the assumption that data are normally distributed, this is problematic. Although some data were likely to be skewed, following consultation with a statistics mailing list, we entered data into RevMan to allow the available information to be summarised. This was based on the assumption that RevVan analysis is able to cope with some degree of skew within the data. </P>
<P>4.2.4 Valid scales<BR/>There are many rating scales available to measure mental-health outcomes within trials. The quality of such scales varies, with some lacking validity and/or reliability. We subsequently set minimum standards for accepting a measurement instrument. These were that psychometric properties of the instrument must have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>) and that the instrument should either be a self-report or completed by an independent rater or relative (not the therapist).</P>
<P>4.2.5 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) - whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated - causing type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where data were presented corrected by a design effect (see below) data were pooled with non-cluster studies.</P>
<P>Where data were reported as if from a non-cluster randomised study, and the analyses were based on the numbers of individuals, with no account taken of the clustering effect, we sought statistical advice from the MRC Biostatistics Unit, Cambridge, UK. They advised that the binary data as presented in the report should be divided by a 'design effect' and that this was calculated using the mean number of families in the groups (m) and the intra-class correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC]. If authors of the study did not or were unable to supply ICC we assumed this to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented continuous data in a table, with an (*) symbol - to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to seek intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where cluster studies were appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis of binary data with other studies was possible using the generic inverse variance technique.</P>
<P>5. Sensitivity analysis <BR/>5.1 Subgroup analysis according to population age with respect to the above outcome measures.<BR/>This was to have been carried out by a meta-regression analysis, factoring in the associated dose and only for pre-designated primary outcomes.</P>
<P>5.2 Subgroup analysis according to medication type (i.e. typical versus atypical antipsychotic) only for pre-designated primary outcomes.<BR/>This was to have been carried out by a meta-regression analysis, factoring in the associated drugs and only for pre-designated primary outcomes.</P>
<P>6. Investigation of heterogeneity<BR/>Firstly, we undertook consideration of all the included studies within any comparison to estimate clinical heterogeneity. Then we used visual inspection of graphs to investigate the possibility of statistical heterogeneity. This was supplemented employing, primarily, the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate included 75%, this was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We did not summate data with 75% or greater I-squared statistic, but presented these separately and investigated the reasons for heterogeneity.</P>
<P>7. Small study bias <BR/>The likelihood of small study bias, and perhaps publication bias, was investigated by entering all data from studies initially identified, as well as those finally selected, into a funnel graph plotting trial effect against trial size (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of the studies please see Included and Excluded Studies tables.</P>
<P>1. Excluded studies<BR/>We excluded a total of 111 studies from the review; the majority (n=86) because they failed to meet our inclusion criteria with respect to age (i.e. 80% of patients shown to be aged 65 years or over), with a further 14 studies excluded as less than 80% of participants had a stated and confirmed diagnosis of schizophrenia. Five studies were not randomised (<LINK REF="STD-Ayers-1960" TYPE="STUDY">Ayers 1960</LINK>, <LINK REF="STD-Haggstrom-1980" TYPE="STUDY">Haggstrom 1980</LINK>, <LINK REF="STD-Harvey-2004b" TYPE="STUDY">Harvey 2004b</LINK>, <LINK REF="STD-Hellewell-2000" TYPE="STUDY">Hellewell 2000</LINK>, <LINK REF="STD-Mohler-1970" TYPE="STUDY">Mohler 1970</LINK>) and one reported different outcome measures than those with which this review was concerned (<LINK REF="STD-Andia-1998" TYPE="STUDY">Andia 1998</LINK> measured plasma homovanillic acid levels in women with schizophrenia). Interventions other than the use of antipsychotic medications for the treatment of schizophrenia were used in three studies - namely the use of amitriptyline-fluphenazine combination versus placebo (<LINK REF="STD-Baldini-1970" TYPE="STUDY">Baldini 1970</LINK>), and treatments for tardive dyskinesia (<LINK REF="STD-Bateman-1979" TYPE="STUDY">Bateman 1979</LINK>, <LINK REF="STD-Glazer-1990" TYPE="STUDY">Glazer 1990</LINK>). Two trials were withdrawn as the study drug (ziprasidone) was not granted a UK licence in time for inclusion in the study (<LINK REF="STD-Singh-2002" TYPE="STUDY">Singh 2002</LINK>, <LINK REF="STD-Woodruff-2002" TYPE="STUDY">Woodruff 2002</LINK>) and one was excluded as the data provided in the paper was unusable and no further details were obtainable from the authors (<LINK REF="STD-Barak-2000" TYPE="STUDY">Barak 2000</LINK>). Finally, we excluded <LINK REF="STD-Friedman-2003" TYPE="STUDY">Friedman 2003</LINK> as it was a review article. </P>
<P>2. Awaiting assessment<BR/>Four studies currently await assessment, all of which require translation, three from Chinese (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>, <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>), and one from Czech (<LINK REF="STD-Vencovsky-1975" TYPE="STUDY">Vencovsky 1975</LINK>).</P>
<P>3. Ongoing studies<BR/>We have identified three ongoing studies (<LINK REF="STD-Lacro-2001" TYPE="STUDY">Lacro 2001</LINK>, <LINK REF="STD-Matkovits_x002d_Gupta-1999" TYPE="STUDY">Matkovits-Gupta 1999</LINK>, <LINK REF="STD-Newcomer-2001" TYPE="STUDY">Newcomer 2001</LINK>) and contacted the authors have been contacted for more information.</P>
<P>4. Included studies<BR/>We identified three studies that met the inclusion criteria (<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK>, <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK>, <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>). All were described as randomised and double-blind. Consent was described in all cases. </P>
<P>4.1 Length of trials<BR/>All trials were restricted to short-term follow-up only (less than 12 weeks). <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> occurred over an 8 week period, preceded by one week where previously prescribed antipsychotic medications were tapered off. The two other studies, <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> and <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>, were restricted to 6 weeks with the former preceded by a 2-5 day wash-out period (for oral antipsychotics),or discontinuation of depot antipsychotics for at least one dose interval before the start of active medication, and the latter preceded by a 2 to 9 day screening period after which they included eligible patients.</P>
<P>4.2 Participants<BR/>All three studies included participants with clearly operationalised diagnoses. In no cases were the patients restricted to those with a diagnosis of schizophrenia alone. One study included people with schizophrenia or schizoaffective disorder (<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK>), one included those with either schizophrenia, schizoaffective disorder or schizophreniform psychosis (<LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>) and one included people with either schizophrenia, paranoia, acute paranoid disorder or atypical paranoid disorder (<LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK>). Where sex was specified, the majority of participants were women whose mean age was in excess of 65 years. All studies report clear exclusion criteria. Some excluded people on the basis of disease severity (<LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> required a minimum BPRS score of 18) and all contained within their exclusion criteria the presence of concomitant mental and/or physical disorders (a diagnosis of substance abuse or dependence during the previous 3 months, major depressive episode in the previous 6 months, major disorders of the nervous system, including dementia and those illnesses associated with abnormal involuntary movements, serious somatic illness including renal or hepatic insufficiency, QTc interval of &gt;500msec). <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> excluded people judged unresponsive to oral antipsychotics (namely risperidone or olanzapine) and <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> excluded those with a history of serious allergic or toxic reaction to any drugs. </P>
<P>4.3 Setting<BR/>
<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> and <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> were described as multicentre, recruiting patients from both hospital and the community in all cases. Also <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> and <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> recruited from nursing homes and 'board and care' homes. </P>
<P>4.4 Study size<BR/>
<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> was the largest study, recruiting 175 people, whilst <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> randomised only 18. Although <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reports a total of 1996 patients recruited after screening, only 59 were aged 65 years or older (mean age 69 years) so only the data on these participants were included in this review. </P>
<P>4.5 Interventions<BR/>The studies used the following oral antipsychotics: risperidone (dose 1-3 mg/day, mean 1.9 mg/day) versus olanzapine (dose 5-20 mg/day, mean 11.1 mg/day) (<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK>); olanzapine (5-20 mg/day, mean 12.4 mg/day) versus haloperidol (5-20 mg/day, mean 8.7 mg/day) (<LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>) and remoxipride (200 mg/day, mean and maximum dose) versus thioridazine (mean 133 mg/day, maximum dose 200 mg/day) (<LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK>).</P>
<P>4.6 Outcomes<BR/>Improvement - <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> defined improvement as a 20% reduction in PANSS (total) scores. From additional data obtained from the author, we were also able to present CGI data dichotomised as improved versus unchanged or worse. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> presented dichotomised data for BPRS results (with a reduction of 40% or more compared with baseline scores), however, these data were on a subset of patients and it the particular proportion included was unclear. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for death, somnolence, insomnia, dizziness, agitation, constipation, headache, diarrhoea and extra-pyramidal adverse effects. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported usable data for dry mouth and constipation. Unfortunately the improvement data from <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> were not presented in a usable fashion. Much of the other improvement data presented by <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>, and <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> were in the form of continuous end-point or change, making comparisons difficult. Making data binary makes it more clinically understandable. Also it may be wasteful of time and effort, if a simple yes/no question on clinical efficacy would suffice rather than a large number of BPRS and PANSS questions. However, the validity of dichotomising is unclear. </P>
<P>4.6.1 Outcome scales: details of the only scales that provided usable data are shown below. Reasons for exclusions of data are given under 'outcomes' in the 'included studies' section.</P>
<P>4.6.1.1 Global state<BR/>4.6.1.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported change data for this scale.</P>
<P>4.6.1.2. Mental state<BR/>4.6.1.2.1. Positive and Negative Symptom Scale - PANSS (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. This scale can be divided into 3 sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> and <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported data for this scale.</P>
<P>4.6.1.2.2. Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms.<LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported data for this scale.</P>
<P>4.6.1.2.3. Montgomery-Asberg Depression Rating Scale -MADRS (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>) <BR/>A 65-item comprehensive psychopathology scale was used to identify the 17 most commonly occurring symptoms in primary depressive illness. Ratings are based on 10 items, with higher scores indicating more symptoms.<LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported data for this scale.</P>
<P>4.6.1.3. Cognitive function <BR/>4.6.1.3.1. Continuous Performance Test - CPT (<LINK REF="REF-Cornblatt-1989" TYPE="REFERENCE">Cornblatt 1989</LINK>)<BR/>In this test of vigilance, patients are asked to press a computer key whenever the same four-digit target stimulus occurs twice in a row. The dependent variable is the signal detection index, which is the response sensitivity for discrimination of target and non-target stimuli. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for this scale.</P>
<P>4.6.1.3.2. Serial Verbal Learning Test - SVLT (<LINK REF="REF-Morris-1989" TYPE="REFERENCE">Morris 1989</LINK>)<BR/>Patients are presented with a ten-item list of words in three separate learning trials. Dependent variables are the total number of words recalled in the three learning trials and at delayed recall. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for this scale.</P>
<P>4.6.1.3.3. Trail Making Test - TMT (<LINK REF="REF-Spreen-1998" TYPE="REFERENCE">Spreen 1998</LINK>)<BR/>A test of visuomotor speed (part A) and the ability to alternate between sets (part B). The time taken to complete the test is the dependent variable. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for this scale.</P>
<P>4.6.1.3.4. Wisconsin Card Sorting Test - WCST (<LINK REF="REF-Heaton-1993" TYPE="REFERENCE">Heaton 1993</LINK>)<BR/>A test of executive functioning, cognitive flexibility, maintenance of a cognitive set and working memory. The dependent variables used are the number of categories completed and the total number of errors. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for this scale.</P>
<P>4.6.1.3.5. Cognitive function - Verbal Fluency Examination - VFE (<LINK REF="REF-Lezak-1997" TYPE="REFERENCE">Lezak 1997</LINK>)<BR/>A test of category and phonologic fluency. The dependent variables are the total scores for category and letter fluency. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for this scale.</P>
<P>4.6.1.4. Adverse effects <BR/>4.6.1.4.1. Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) <BR/>This has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported data for this scale.</P>
<P>4.6.1.4.2. Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from 0 - normal to 3 - severe. In addition, there is an item for rating global severity (from 0 - absent to 5 - severe). A low score indicates low levels of akathisia. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported data for this scale.</P>
<P>4.6.1.4.3. Extrapyramidal Syndrome Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder. <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported data for this scale.</P>
<P>4.6.1.4.4. Simpson-Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported data for this scale.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>All included studies were said to be randomised but none described how this was undertaken. No study stated that those in charge of allocation were blind to the method. We categorised all trials 'B' (see methods section).</P>
<P>2. Blindness<BR/>All studies were described as being double-blind, but we could find no testing of this.</P>
<P>3. Loss to follow up<BR/>
<LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> and <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> analysed their data on an intention-to-treat basis using LOCF (last observation carried forwards) analysis. Once participants leave a study, unless the trialists continue to follow and collect data, assumptions have to be made about outcome. Although this is a common method of accounting for missing observations it could introduce bias, and may well overestimate any treatment effect.</P>
<P>Drop-out rates were variable (from 11% in <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK>, to 23% in <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK>), however these trials described the patient disposition well, clearly informing the reader of the reason the individual withdrew from the study. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> did not include specific data regarding participants who left the study early. </P>
<P>4. Data reporting <BR/>Overall much of the data we found could not be used due to poor reporting. Findings which are presented as graphs, in percentiles or just reported as inexact p-values, are often of little use to a reviewer. Many studies failed to provide standard deviations when reporting mean changes on a particular outcome measure. We are seeking further data from the first authors of relevant trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. Search<BR/>Our initial search identified over 300 citations. Many studies were reported in different media and it was important to clarify which papers and conference proceedings related to the same study and the same patients. </P>
<P>It was clear from the references that most were not relevant and we went on to retrieve all material available relating to 114 studies. As described above, only three trials met our inclusion criteria. A further 49, however, included some people over 65 years of age. <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> included 1996 patients with schizophrenia over the age of 18 of whom 339 were aged 50 years or over, 117 were aged 60 years or over and 59 were aged 65 years or over. Patients 65 years and over subsequently made up 3% of the total included in the study (in which all participants were aged 18 years and over), 17% of participants were aged 50 years and over and 50% of patients aged 60 years and over. The data on this sub-group were not presented separately but were kindly supplied for our use in this review by the company (Eli Lilly). Using these proportions as a guide we estimated the number of patients aged 65 years or over in these 49 studies. Approximately 450 patients aged 65 years or over may have been included in these studies. This compares with the 253 patients we were able to include in our analysis.<B> </B>If studies likely to have less than ten people aged 65 years and over are excluded, that may still leave eight studies with a total of over 300 patients aged 65 years or over. There were a further 12 studies who reported no upper age range. If it is assumed that, like <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>, they included patients aged 65 years or over at a proportion of 3%, then there may be a further 127 patients in this age group that have been excluded from the review. Six of these studies could, by the same assumption, have included ten or more participants aged 65 years or over, with a total of 103 patients. Data on possibly over 400 patients in the target population of the review could subsequently have been missed because separate data for them was unobtainable.</P>
<P>2. COMPARISON 1: THIORIDAZINE versus REMOXIPRIDE<BR/>Only <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> (n=18) compared the efficacy of thioridazine with remoxipride.</P>
<P>2.1 Leaving the study early<BR/>The only usable data available were on leaving the study early. The patient who left the thioridazine arm did so because of adverse effects (somnolence), whilst the person who left the remoxipride arm refused to remain in hospital (n=18, RR 1.0 CI 0.1 to 13.6).</P>
<P>3. COMPARISON 2: RISPERIDONE versus OLANZAPINE<BR/>Only <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> (n=175) compared the efficacy of risperidone with olanzapine</P>
<P>3.1 Death: suicide and natural causes<BR/>One patient in the olanzapine arm of the study died of a myocardial infarction during the 8 weeks of the study period. Investigators did not relate this to the medication and there were no statistically significant differences between the two groups (RR 0.34 CI 0.01 to 8.2).</P>
<P>3.2 Global state: not improved or worse.<BR/>
<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> did not report these data in the original paper, however, we were able to obtain the data from the company (Janssen). Numbers of patients in the seven categories from very much improved, through unchanged to very much worse were presented. We were subsequently able to dichotomise this as improved versus not improved or worse. We found no statistically significant differences between the two interventions (n= 171, RR 1.26 CI 0.8 to 1.9).</P>
<P>3.3 Mental state: Not improved (PANSS decrease of less than 20%)<BR/>The trialists defined clinical improvement as a PANSS total score reduction of greater than or equal to 20%. Again these data were not published in the original paper, but information was available through direct contact with Janssen. These data revealed that this degree of improvement was achieved in 58% of the risperidone group compared with 59% of those allocated olanzapine (n=171, RR 0.98 CI 0.8 to 1.3). </P>
<P>3.3.1 Mental state: Average endpoint score (PANSS, high=poor)<BR/>
<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> presented end point data for PANSS total (n=171, WMD 0.00 CI -5.45 to 5.45), together with PANSS positive subscale (n=171, WMD 0.20 CI -1.8 to 2.2) and the negative subscale (n=171, WMD -0.30 CI -2.3 to 1.7). This research group found no indication that either risperidone or olanzapine was more effective for this outcome. </P>
<P>3.4 Leaving the study early<BR/>
<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> reported 'leaving the study early'. Twenty four patients discontinued treatment in the risperidone group compared with 17 in the olanzapine group (n=175, RR 1.43 CI 0.8 to 2.5).</P>
<P>3.5 Cognitive function<BR/>Trialists sub-divided assessments of cognitive function into attention, memory and executive domains and <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> used two methods of assessing the attention component of cognitive function (CPT'd and Trail-making part A). In neither case were there any statistically significant differences identified between the two interventions (CPT'd WMD -0.14 CI -0.4 to 0.10); Trail-making part A (WMD -0.59 CI -13.7 to 12.5). </P>
<P>Similarly <LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> presented data with respect to two methods of assessing the memory domain of cognitive function (Serial verbal test, total learning and Delayed recall). In neither case did data reveal significant differences between the two interventions (Serial verbal test, total learning WMD 0.34 CI -1.1 to 1.8; Delayed recall WMD 0.11 CI -0.5 to 0.7). </P>
<P>
<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> used a number of tools to assess the executive domain of cognitive function (Trail making part B, WCST categories, WCST total errors, verbal fluency total). None of the tests yielded statistically significant differences between the two interventions (Trail making part B WMD -8.41 CI -26.95 to 10.1; WCST categories WMD 0.10 CI -0.3 to 0.5; WCST total errors WMD -3.93 CI -10.1 to 2.3; verbal fluency total WMD 0.78 CI -2.4 to 3.97). </P>
<P>4. COMPARISON 3: OLANZAPINE versus HALOPERIDOL (all short term data)<BR/>Only <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> compared the efficacy of olanzapine with haloperidol. In the original paper, data on the over 65 age group were not published separately. However, we were able to obtain data on this group from the drug company (Eli Lilly). These data are from the sub-group of 59 elderly people (total trial size 1996).</P>
<P>4.1 Mental state<BR/>Change data revealed no statistically significant differences between olanzapine and haloperidol for BPRS (WMD -3.60 CI -10.8 to 3.6). This also applied to PANSS scores (total PANSS WMD -6.00 CI -18.3 to 6.3; PANSS Positive subscale WMD 0.00 CI -3.3 to 3.3; Negative subscale WMD -1.90 CI -5.4 to 1.6). MADRS scores were also equivocal (WMD -4.70 CI -10.3 to 0.9). </P>
<P>4.2 Adverse events<BR/>4.2.1 Average change scores on continuous data scales<BR/>Data were available for akathisia (AIMS), and extrapyramidal adverse effects (SAS and BAS). There were no statistically significant differences between olanzapine and haloperidol with respect to the frequency or severity of adverse events (BAS WMD -1.00 CI -1.8 to -0.2; AIMS WMD -0.30 CI -2.8 to 2.2; SAS WMD -2.90 CI -6.3 to 0.5).</P>
<P>4.2.2 Discrete events<BR/>Data were available for the incidence of dry mouth and constipation. Although the trial found a slightly increased incidence of dry mouth with olanzapine, this was not statistically significant (n=59, RR 0.34 CI 0.02 to 5.1). Nor were there statistically significant differences found between the olanzapine and haloperidol groups with respect to constipation (n=59, RR 0.51 CI 0.1 to 2.8).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Limited data<BR/>We found few studies fulfilling our selection criteria. </P>
<P>All available data were short term, with trials restricting data collection to 6 or 8 weeks. Considering that schizophrenia is a relapsing and remitting disorder and drug treatments are likely to be used by people with schizophrenia for long periods, one would expect more long-term data to be available. The short term nature of the included trials limits the applicability of the findings of this review for routine care. </P>
<P>Data were often not used because of high numbers leaving the study early. The degree of loss to follow-up is common in similar studies, but rare in everyday practice. This also casts doubt on the applicability of findings to routine care. </P>
<P>Much global effect, mental state and cognitive function data are either missing or unusable despite the efforts we made to contact authors to acquire the necessary information. In addition, it is disappointing and remarkable that despite considerable investment in clinical trials, data remain so limited on tolerability, social functioning, death, satisfaction, quality of life, direct and indirect costs of treatment. </P>
<P>2. Applicability of findings<BR/>Two of the three included trials were international multicentre trials (<LINK REF="STD-Harvey_x002f_Jeste-2003" TYPE="STUDY">Harvey/Jeste 2003</LINK> and <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>) however they both tended to reflect a western bias in patient recruitment and this should be taken into consideration when clinicians consider the use of antipsychotic medications in different care settings. Participants were drawn from both hospital inpatient and community settings and had operationally diagnosed disorders mostly uncomplicated by co-morbidity. The large <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> study may be considered to be more representative of day-to-day practice, as those with co-morbid disorders were not excluded.</P>
<P>3. Reporting of adverse data<BR/>Only <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK> reported usable adverse event data. Although trialists in the other studies stated an intention to collect such data, they either failed to report it, or reported it in an unusable form. Therefore, the potential for rare adverse effects having been ignored cannot be overlooked. </P>
<P>4. The search<BR/>Several of the studies were reported many times. Without the use of unique study identifiers this gives the impression that there are more data than actually exist and facilitates erroneous double-counting. Although we have found no evidence to suggest that authors have attempted to conceal the fact that the large numbers of presentations relate to a limited number of studies, the inclusion of the unique company trial codes in each presentation would have facilitated piecing together the linked trials. </P>
<P>5. COMPARISON: THIORIDAZINE versus REMOXIPRIDE<BR/>One small study could be included in this comparison. Data were only available for the outcome of leaving the study early and no differences between treatments were found. Remoxipride is off the market and so this comparison is now of historical interest only. Thioridazine is now not as widely prescribed in the West as it has been in previous years and it has been taken off the market in many countries. However it is still available in many countries including India, Thailand and Chile. </P>
<P>6. COMPARISON: RISPERIDONE versus OLANZAPINE<BR/>It would have been surprising to find any differences between the two compounds in such a small study and, indeed, none were found. The one death in this study may have been a chance event and should not necessarily be interpreted as an untoward effect of either drug. </P>
<P>These are important drugs with many clinicians considering using them in this age group despite the recent concerns about increased risk of mortality (<LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>). More data are needed. This trial should be replicated so that possible differences between the compounds (such as those evident in the review of these two drugs in the younger adult population (<LINK REF="REF-Jayaram-2005" TYPE="REFERENCE">Jayaram 2005</LINK>)) are brought to light.</P>
<P>7. COMPARISON: OLANZAPINE versus HALOPERIDOL<BR/>Only 56 people of the correct age group have been involved in a trial of these two compounds. The study was too short and small to really find any important differences, although we do recognise that it was never designed to focus specifically on the elderly. With the recent difficulties of risperidone (<LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>), olanzapine may well be being used more widely and more studies focusing on olanzapine are awaited. Until then the advantage of this atypical antipsychotic for the elderly over the older drug haloperidol remains in doubt.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For elderly people with schizophrenia. <BR/>For elderly people with schizophrenia, available evidence would suggest that there is little to choose between risperidone, olanzapine, haloperidol, thioridazine and remoxipride for the treatment of the mental state effects or cognitive effects of schizophrenia. Since publication of the study by <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK>, both thioridazine and remoxipride have been withdrawn from use and are no longer an option for treatment of schizophrenia in any age group. </P>
<P>2. For clinicians<BR/>In these small trials, most recipients of antipsychotic medication were only studied for a maximum of eight weeks. Based on the data which is currently available, this systematic review can provide few reliable conclusions about the use of antipsychotic medications in the treatment of schizophrenia in the elderly. In the absence of any robust evidence, the clinician must balance the possible benefits against the potential adverse effects of treatment and continue to extrapolate from evidence which was not focused on elderly people. Important ethical questions are raised by current prescribing practices for elderly people with schizophrenia. It is difficult to know whether current practice is justified outside of a well designed, conducted and reported randomised study. </P>
<P>3. For managers/policy makers.<BR/>Atypical antipsychotics are expensive when compared with typical antipsychotics. For those making decisions on cost-effectiveness and cost-utility, there are currently no useful trial-derived data to help decision making. Consequently, decisions continue to made based on opinion and habit.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>Clear and strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) for all outcomes would have resulted in this review being more informative. Denominator data were not always clearly presented and some results that were described as 'significant' failed to report raw data. </P>
<P>2. Specific<BR/>We had to inspect a great number of presentations of the few trials included in this review and it is likely that many more may still be untraced. Using specific trial identifiers within the multiple publications would greatly decrease confusion over identification of the source trial.</P>
<P>Funders of studies may wish to make this important group of people with schizophrenia a priority for future research. Certainly, more well-planned, conducted and reported randomised controlled trials are needed to run, over longer periods, and address important, relevant outcomes. Funding that is as free from conflicts of interest as possible is needed. High quality trial-derived data relating to hospital admission, satisfaction with care, carer burden and important side effects are lacking. Dichotomous, clinically useful data relating to mental state and behaviour need replication and expansion. Useful cost-effectiveness data must be a research priority.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We wish to thank the staff at the editorial base of Cochrane Schizophrenia Group, in particular, John Rathbone, Clive Adams and Mark Fenton who provided much support for this review. We would also like to thank all authors and drug companies who provided additional information to aid our review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Richard Marriott - took the lead in starting the review and collaborated with the co-reviewers in writing the protocol and carrying out the review.</P>
<P>Wendy Neil - collaborated in writing the protocol and carrying out the review.</P>
<P>Susie Waddingham - collaborated in writing the protocol and carrying out the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-21 13:59:35 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey_x002f_Jeste-2003" NAME="Harvey/Jeste 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>*Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G</AU>
<TI>International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>6</NO>
<PG>638-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003460986"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Gharabawi G</AU>
<TI>Cognition in elderly patients with schizophrenia: risperidone versus olanzapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S77</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.1.W.013"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Gharabawi G</AU>
<TI>Risperidone and cognition in schizophrenic elderly</TI>
<SO>XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2002342863"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Mao L, Napolitano J, Gharabawi G</AU>
<TI>Cognition in elderly schizophrenic patients: risperidone vs olanzapine</TI>
<SO>European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden)</SO>
<YR>2002</YR>
<NO>Suppl 1</NO>
<PG>192s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P46.15 ABSTRACT 426"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Mao L, Napolitano J, Gharabawi G</AU>
<TI>Improved cognition in elderly schizophrenic patients: risperidone versus olanzapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl.1</NO>
<PG>28</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2079#"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Napolitano JA, Mao L, Gharabawi G</AU>
<TI>Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>9</NO>
<PG>820-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003380232"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeste D, Madhusoodanan S, Barak Y, Martinez RA, Mahmoud R, Kershaw P</AU>
<TI>Risperidone and olanzapine in elderly patients with schizophrenia and schizoaffective disorder</TI>
<SO>International Psychogeriatrics</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>295S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0195113456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jeste DV, Madhusoodanan S, Barak F, Martinez RA</AU>
<TI>Risperidone versus olanzapine in elderly patients with schizophrenia</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NR754 Thursday, May 10, 12:00 p.m.-2:00 p.m"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jeste DV, Madhusoodanan S, Barak F, Martinez RA</AU>
<TI>Risperidone versus olanzapine in elderly patients with schizophrenia</TI>
<SO>Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CRISP Grant Number - 5R29MH56938-04"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lasser RA, Mao L, Gharabawi G</AU>
<TI>Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>2-3</NO>
<PG>163-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15061249"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2004015909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phanjoo-1990" NAME="Phanjoo 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phanjoo AL, Link C</AU>
<TI>Remoxipride versus thioridazine in elderly psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1990</YR>
<VL>358</VL>
<PG>181-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91050687"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1978481"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1997" NAME="Tollefson 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Andersen SW, Tollefson GD, Sanger T</AU>
<TI>Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1967-04709-001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burns PR, Reams SG, Sanger TM, Beasley CM Jr</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67129859"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6021696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burns PR, Reams SG, Sanger TM, Beasley CM Jr</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76230764"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 779704"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilmore J, Kinon BJ, Basson BR, Tollefson GD</AU>
<TI>Effect of long term olanzapine treatment on weight change in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S155</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01236"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy JS, Jeste D, Kaiser CJ, Golsham S, Maguire GA, Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M, Gilmore JA, Breier A</AU>
<TI>Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>1013-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14618553"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003491563; PsycINFO 2003-10341-008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kuntz AJ, Sanger TM, Beasley CM</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11; San Diego, USA</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92302393"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1609047"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lane LM, Burns PR, Reams SC, Sanger TM, Beasley CM Jr</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1998 P2042"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reams SG, Sanger TM, Beasley CM</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>151</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82248457"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6124989"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, Wei H</AU>
<TI>Olanzapine for psychotic conditions in the elderly</TI>
<SO>Psychiatric Annals</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>191-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, GraffeoKA, Thieme ME</AU>
<TI>Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD</AU>
<TI>Treatment consideration for comorbid mood disorders in schizophrenic patients</TI>
<SO>6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Altman-1973" NAME="Altman 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altman H, Mehta D, Evenson RC, Sletten IW</AU>
<TI>Behavioral effects of drug therapy on psychogeriatric inpatients: II. Multivitamin supplement</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1973</YR>
<VL>21</VL>
<NO>6</NO>
<PG>249-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73194804"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 51-03624; PMID 4145685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andia-1998" NAME="Andia 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andia I, Zumarraga M, Zabalo MJ, Bulbena A, Davila R</AU>
<TI>Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>1</NO>
<PG>20-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98104422"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1998040523; PMID 9442340"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angst-1973" NAME="Angst 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angst J, Frei M, Scharfetter Chr</AU>
<TI>The depot neuroleptic agent fluspirilene</TI>
<TO>Das Depotneurolepticum Fluspirilen. Klinische Pruefung im offenen Versuch und als Doppelblindstudie im Vergleich zu Fluphenazin Decanoat</TO>
<SO>Pharmakopsychiatrie Neuropsychopharmakologie</SO>
<YR>1973</YR>
<VL>6</VL>
<NO>1</NO>
<PG>13-28</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74281360"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4602371"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayers-1960" NAME="Ayers 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayers CM</AU>
<TI>The relative value of various somatic therapies in schizophrenia</TI>
<SO>Journal of Neuropsychiatry</SO>
<YR>1960</YR>
<VL>1</VL>
<PG>154-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98135874"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9477007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azorin-2001" NAME="Azorin 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I</AU>
<TI>A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>8</NO>
<PG>1305-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21373812"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11481167; CINAHL 2001114781"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldini-1970" NAME="Baldini 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldini JT, Neary ER</AU>
<TI>Controlled trials of an amitriptyline-fluphenazine combination in depressive neuroses and psychoses: a collaborative study</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>2</NO>
<PG>84-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70113586"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4984324"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bamrah-2000" NAME="Bamrah 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Bamrah S</AU>
<TI>A multicentre, double-blind, randomised, parallel group comparison of seroquel and haloperidol in the treatment of elderly patients presenting with dementia and psychosis</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="National Research Register N0262026571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2000" NAME="Barak 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barak Y, Shamir E, Weizman R</AU>
<TI>Risperidone compared with typical neuroleptic treatment in elderly schizophrenic patients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S122</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01119"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2002" NAME="Barak 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R</AU>
<TI>Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2002</YR>
<VL>29</VL>
<PG>1199-202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="22339706"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 12452546"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-1979" NAME="Bateman 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DN, Dutta DK, McClelland HA, Rawlins MD</AU>
<TI>Metoclopramide and haloperidol in tardive dyskinesia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>135</VL>
<PG>505-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80131367"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 43755"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DN, Dutta DK, McClelland HA, Rawlins MD</AU>
<TI>The effect of metoclopramide and haloperidol on tardive dyskinesia</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1979</YR>
<VL>66</VL>
<NO>3</NO>
<PG>475-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80110410"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 526754"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2003" NAME="Beasley 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Sutton VK, Hamilton SH, /Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD</AU>
<TI>A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>582-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berman-1995" NAME="Berman 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berman I, Allan ER, Pappas D, Sison CE, Merson A</AU>
<TI>The cognitive effect of risperidone in elderly schizophrenic patients a pilot double-blind comparison study with haloperidol</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80131367"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 43755"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berman I, Merson A, Allan E, Alexis C, Losonczy M</AU>
<TI>Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison study with haloperidol</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>3</NO>
<PG>552</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75116103"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 235013"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bora-1968" NAME="Bora 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bora G</AU>
<TI>Comparison of dosage ranges of carphenazine and trifluoperazine in elderly chronic schizophrenics</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1968</YR>
<VL>29</VL>
<NO>10</NO>
<PG>695-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69150440"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4887393"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bossie-2003" NAME="Bossie 2003" YEAR="2003,">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bossie C, Lasser R, Gharabawi G</AU>
<TI>Low or absent pain and injection site effects with long-acting risperidone</TI>
<SO>156th Annual Meeting of the American Psychiatric Association, San Francisco, USA</SO>
<YR>2003, May 17-22</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brauzer-1968" NAME="Brauzer 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brauzer B, Goldstein BJ</AU>
<TI>Comparative effects of intramuscular thiothixene and trifluoperazine in psychotic patients</TI>
<SO>Journal of Clinical Pharmacology and the Journal of New Drugs</SO>
<YR>1968</YR>
<VL>8</VL>
<NO>6</NO>
<PG>400-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69087651"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4883787"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-1999" NAME="Breier 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Alan B, Hamilton SH</AU>
<TI>Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<PG>144</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-04-22"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breier A, Hamilton SH</AU>
<TI>Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>4</NO>
<PG>403-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99171102"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10071708"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Breier AF, Hamilton SH</AU>
<TI>Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78241397"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 355182"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buruma-1982" NAME="Buruma 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buruma OJ, Roos RA, Bruyn GW, Kemp B, van der Velde EA</AU>
<TI>Tiapride in the treatment of tardive dyskinesia</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1982</YR>
<VL>65</VL>
<NO>1</NO>
<PG>38-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82155989"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6121443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cantillon-1998" NAME="Cantillon 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M</AU>
<TI>Quetiapine fumarate reduces aggression</TI>
<SO>11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11; San Diego, USA</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95208930"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7694918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canuso-2003" NAME="Canuso 2003" YEAR="2003,">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canuso CM, Bossie C, Lasser R, Gharabawi G</AU>
<TI>Reduced serum prolactin levels following long-acting treatment with risperidone</TI>
<SO>156th Annual Meeting of the American Psychiatric Association, San Francisco, USA</SO>
<YR>2003, May 17-22</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassano-1975" NAME="Cassano 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassano GB, Castrogiovanni P, Conti L, Bonollo L</AU>
<TI>Sulpiride versus haloperidol in schizophrenia: a double blind comparative trial</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>17</VL>
<NO>2</NO>
<PG>189-201</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 54-01569"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1979" NAME="Chouinard 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Jones BD</AU>
<TI>Evidence of brain dopamine deficiency in schizophrenia</TI>
<SO>Canadian Journal of Psychiatry (Revue Canadienne de Psychiatrie)</SO>
<YR>1979</YR>
<VL>24</VL>
<NO>7</NO>
<PG>661-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1980059772"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1983" NAME="Chouinard 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Ross Chouinard A, et al</AU>
<TI>Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment</TI>
<SO>Psychopharmacology</SO>
<YR>1983</YR>
<VL>81</VL>
<NO>2</NO>
<PG>100-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1983233845"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Citrome-2001" NAME="Citrome 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Citrome LL, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P, McEvoy JP, Lieberman JA</AU>
<TI>Atypical antipsychotics and hostility in schizophrenia: a double-blind study</TI>
<SO>Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2033#"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cody-1977" NAME="Cody 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cody J, Robinson AM</AU>
<TI>The effect of low-cost maintenance medication on the rehospitalization of schizophrenic outpatients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1977</YR>
<VL>134</VL>
<PG>73-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77085236"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 831545"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2001" NAME="Conley 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Mahmoud R</AU>
<TI>A randomised double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>5</NO>
<PG>765-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coryell-1998" NAME="Coryell 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coryell W, Miller D D, Perry P J</AU>
<TI>Haloperidol plasma levels and dose optimization</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>1</NO>
<PG>48-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82155989"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6121443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crow-1986" NAME="Crow 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crow TJ, MacMillan JF, Johnson AL, Johnstone EC</AU>
<TI>A randomised controlled trial of prophylactic neuroleptic treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>148</VL>
<PG>120-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86188455"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2870753"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csernansky-2002" NAME="Csernansky 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csernansky JG, Mahmoud R, Brenner R, The Risperidone-USA-79 Study Group</AU>
<TI>A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21636672"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11777998"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1999" NAME="Daniel 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M</AU>
<TI>Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6 week placebo controlled trial. Ziprasidone Study Group</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>5</NO>
<PG>491-505</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99208909"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10192829"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reeves K, Harrigan EP</AU>
<TI>Two fixed doses of ziprasidone efficacy and safety</TI>
<SO>10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reeves KR</AU>
<TI>The efficacy and safety of two fixed doses of ziprasidone in schizophrenia</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91050687"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1978481"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jong-1965" NAME="de Jong 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong J</AU>
<TI>Efficacy of phenothiazines without antiparkinson drugs</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1965</YR>
<VL>26</VL>
<NO>11</NO>
<PG>702-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66040624"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5320745"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delwaide-1979" NAME="Delwaide 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delwaide PJ, Desseilles M</AU>
<TI>Controlled therapeutic study of spontaneous bucco-linguo-facial dyskinesias (author's transl)</TI>
<TO>Etude therapeutique controlee des dyskinesies bucco-linguo-faciales spontanees</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1979</YR>
<VL>55</VL>
<NO>35-6</NO>
<PG>1585-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97392141"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9248874"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denijs-1973" NAME="Denijs 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denijs EL, Vereecken JL</AU>
<TI>Pimozide (orap, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up</TI>
<SO>Psychiatria Neurologia Neurochirurgia</SO>
<YR>1973</YR>
<VL>76</VL>
<NO>1</NO>
<PG>47-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73162821"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4699105"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dick-1975" NAME="Dick 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dick P, Remy M, Rey Bellet JJ</AU>
<TI>Comparison of two antipsychotic drugs: chlorpromazine and clozapine</TI>
<TO>Essai de comparaison de deux antipsychotiques: la chlorpromazine et la clozapine</TO>
<SO>Therapeutische Umschau</SO>
<YR>1975</YR>
<VL>32</VL>
<NO>8</NO>
<PG>497-500</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76013838"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1099714"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Docherty-2002" NAME="Docherty 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Docherty JP, Napolitano J, Mahmoud RA, Martinez RA, Lasser RA, Pandina GJ, Gharabawi G</AU>
<TI>Anticholinergic effect of atypical antipsychotics in elderly patients</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NR142"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tune L, Mulsant B, Gharabawi G</AU>
<TI>Anticholinergic effect of atypical antipsychotics in elderly patients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>S314</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolnak-2001" NAME="Dolnak 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolnak DR, Rapaport MH</AU>
<TI>A prospective, randomised, double-blind study examining functioning in schizophrenic patients treated with olanzapine and risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1,2</NO>
<PG>225-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekblom-1974" NAME="Ekblom 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ekblom B, Haggstrom JE</AU>
<TI>Clozapine (Leponex) compared with chlorpromazine - a double blind evaluation of pharmacological and clinical properties</TI>
<SO>Current Therapeutic Research</SO>
<YR>1974</YR>
<NO>9</NO>
<PG>945-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 53-05854"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elie-1975" NAME="Elie 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Elie R, Gagnon MA, Gauthier R, Jequier JC</AU>
<TI>Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia</TI>
<TO>Effets d'un sevrage neuroleptique sur le syndrome extrapyramidal medicamenteux de la schizophrenie chronique</TO>
<SO>Union Medicale du Canada</SO>
<YR>1975</YR>
<VL>104</VL>
<NO>6</NO>
<PG>909-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76179130"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 772906"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-1999" NAME="Emsley 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emsley RA, Bailey P, Jones AM, Raniwalla J</AU>
<TI>Efficacy of quetiapine fumarate in partial responders</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66040624"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5320745"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emsley RA, Raniwalla J, Bailey P, Jones AM</AU>
<TI>Efficacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S267</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98135874"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9477007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-2000" NAME="Emsley 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emsley RA, Raniwalla J, Jones AM</AU>
<TI>Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia</TI>
<SO>Poster presented at 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11, Davos, Switzerland</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-04-22"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-2000" NAME="Evans 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Evans M</AU>
<TI>Multi-centre double blind randomised parallel group comparison of seroquel and haloperidol in the treatment of elderly patients presenting with dementia, psychoses</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="National Research Register N0279034588"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-2003" NAME="Feldman 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A</AU>
<TI>Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>998-1004</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003383256"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzgerald-1969" NAME="Fitzgerald 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald CH</AU>
<TI>A double-blind comparison of haloperidol with perphenazine</TI>
<SO>Current Therapeutic Research</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>8</NO>
<PG>515-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CRISP Grant Number - 5K02MH01510-04"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-2003" NAME="Friedman 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman JH</AU>
<TI>Atypical antipsychotics in the EPS-vulnerable patient</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>Suppl. 1</NO>
<PG>39-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="2003006556"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garry-1966" NAME="Garry 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garry J, Hill E</AU>
<TI>A controlled comparative trial of chlorpromazine and benzquinamide in chronic schizophrenia</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1966</YR>
<VL>2</VL>
<NO>6</NO>
<PG>594-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1967-04709-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1988" NAME="Gerlach 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J</AU>
<TI>Tardive dyskinesia: pathophysiological mechanisms and clinical trials</TI>
<SO>Encephale</SO>
<YR>1988</YR>
<VL>14</VL>
<PG>227-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68286294"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4872367"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazer-1985" NAME="Glazer 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Naftolin F, Morgenstern H</AU>
<TI>Estrogen replacement and tardive dyskinesia</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1985</YR>
<VL>10</VL>
<NO>3</NO>
<PG>345-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86043227"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2865766"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazer-1990" NAME="Glazer 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Hafez H</AU>
<TI>A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia</TI>
<SO>Schizophrenia Research</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>5-6</NO>
<PG>315-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91129137"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1980827"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazer-1997" NAME="Glazer 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Johnstone BM</AU>
<TI>Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>Suppl 10</NO>
<PG>50-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1997-05675-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gregor-1999" NAME="Gregor 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Gregor K, Hamilton S, Edgell E</AU>
<TI>Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<PG>152</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-08-20"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gregor KJ, Allicar MP, Lilliu H, Olivier V, Le Pen C, Gavart S</AU>
<TI>An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<NO>Suppl 1</NO>
<PG>S161</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01257"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1974" NAME="Gross 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gross HS</AU>
<TI>A double-blind comparison of once-a-day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>7</NO>
<PG>696-705</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1967-04709-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haggstrom-1980" NAME="Haggstrom 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haggstrom J-E</AU>
<TI>Sulpiride in tardive dyskinesia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>2</NO>
<PG>164-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0164101907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1964" NAME="Hanlon 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Nussbaum K, Wittig B, Hanlon DD, Kurland AA</AU>
<TI>The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients</TI>
<SO>Journal of New Drugs</SO>
<YR>1964</YR>
<VL>4</VL>
<PG>52-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1967-04709-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1992" NAME="Harris 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran Johnson TK, Jeste DV</AU>
<TI>High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1992</YR>
<VL>28</VL>
<NO>1</NO>
<PG>87-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92302393"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1609047"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1997" NAME="Harris 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harris MJ, Paulsen JS, Lacro JP, /Rockwell E, Jeste DV</AU>
<TI>Neuroleptic maintenance treatment in the elderly</TI>
<SO>American Psychiatric Association, 150th Annual Meeting, San Diego</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2002" NAME="Harvey 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey P, Meltzer H, Green M</AU>
<TI>Long term cognitive effects of risperidone treatment in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<NO>Suppl 1</NO>
<PG>S154</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01228"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Lyons BE, Mahmoud R</AU>
<TI>Long term cognitive effects of risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<NO>1</NO>
<PG>200-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99208909"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10192829"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Long-term cognitive effects of risperidone treatment in schizophrenia</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NR343 Tuesday, May 16, 3:00 p.m.-5:00 p.m"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Long-term cognitive effects of risperidone treatment in schizophrenia</TI>
<SO>52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-10-89"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2003" NAME="Harvey 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey P, Meltzer HY, Green MP</AU>
<TI>Cognitive effects of risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany</SO>
<YR>2001</YR>
<NO>Suppl. 1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="7th World Congress of Biological Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 P021-48"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Melzer H, Green M</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>8</NO>
<PG>123S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P02.4 ABSTRACT 155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Green MF, McGurk SR, Meltzer HY</AU>
<TI>Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomised study</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>404-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Mahmoud R, Meltzer HY, Green MP</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey)</SO>
<YR>2001</YR>
<NO>3</NO>
<PG>257</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2033#"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Green M</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="7th World Congress of Biological Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 P021-48"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Green MF</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - June 2, Boca Raton, Florida, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0164101907"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="153rd Annual  Meeting of the American Psychiatric Association [CD-ROM]: MARATHON Multimedia, 2000 NR342"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NR342 Tuesday, May 16, 3:00 p.m.-5:00 p.m"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia</TI>
<SO>52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-10-89"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2004a" NAME="Harvey 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Simpson GM, Loebel A</AU>
<TI>Effect of ziprasidone vs olanzapine on cognition in schizophrenia: a double-blind study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl.1</NO>
<PG>S125</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.2.W.032"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Simpson GM, Loebel A</AU>
<TI>Ziprasidone vs olanzapine for cognitive function in schizophrenia</TI>
<SO>The Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Supplement 3</NO>
<PG>S293</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Hallo P.2.093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Simpson G, Horne R, Weiden PJ, Bari M, Romano SJ</AU>
<TI>Effects of ziprasidone on cognitive function in patients with schizophrenia: results of a double-blind trial vs. olanzapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl.1</NO>
<PG>195</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-10-89"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Simpson G, Horne R, Weiden PJ, Bari M, Romano SJ</AU>
<TI>Ziprasidone vs olanzapine for cognitive function in schizophrenia</TI>
<SO>European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden)</SO>
<YR>2002</YR>
<NO>Suppl 1</NO>
<PG>100s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P02.4 ABSTRACT 155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Simpson GM, Loebel A</AU>
<TI>Ziprasidone versus olanzapine in improving cognition in schizophrenia</TI>
<SO>3rd International Conference on Early Psychosis; 2002 Sep 26-28; Copenhagen, Denmark</SO>
<YR>2002</YR>
<PG>69-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P02.03"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Harvey PD, Simpson GM, Weiden PJ, Loebel A</AU>
<TI>Ziprasidone vs Olanzapine for Cognitive Function in Schizophrenia</TI>
<SO>Poster supplied by company</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Hallo P.2.093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Siu CO, Romano S</AU>
<TI>Randomised, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.</TI>
<SO>Psychopharmacology</SO>
<YR>2004</YR>
<VL>172</VL>
<PG>324-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2004b" NAME="Harvey 2004b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer H, Romano SJ</AU>
<TI>Cognitive function in stable outpatients switched to ziprasidone</TI>
<SO>European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden)</SO>
<YR>2002</YR>
<NO>Suppl 1</NO>
<PG>99s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P02.3 ABSTRACT 154"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Meltzer H, SimpsonGM, Potkin SG, Loebel A, Siu C, Romano SJ</AU>
<TI>Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>66</VL>
<PG>101-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Meltzer HY, Romano S</AU>
<TI>Improvement in cognition following a switch to open label ziprasidone from olanzapine, risperidone and conventional antipsychotics</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S161</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01258"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Meltzer HY, Romano S</AU>
<TI>Improvement in cognition following a switch to open label ziprasidone from olanzapine, risperidone and conventional antipsychotics</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>S288</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="13th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P2018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Romano SJ</AU>
<TI>Improvement in cognition following a switch to open label ziprasidone in outpatients with schizophrenia treated with conventional antipsychotics, olanzapine or risperidone</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="153rd Annual  Meeting of the American Psychiatric Association [CD-ROM]: MARATHON Multimedia, 2000 NR344"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heck-2000" NAME="Heck 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heck AH, Haffmans PMJ, De Groot IW, Hoencamp E</AU>
<TI>Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: A double-blind, multi-center trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>2-3</NO>
<PG>97-105</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20570029"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11120421; EMBASE 2000441700"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellewell-1998a" NAME="Hellewell 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hellewell JSE, Cameron-Hands D, Cantillon M</AU>
<TI>Seroquel: evidence for efficacy in the treatment of hostility and aggression</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1,2</NO>
<PG>154</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellewell-1998b" NAME="Hellewell 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hellewell JSE, Cameron Hands D, McKellar J</AU>
<TI>'Seroquel' : an effective atypical antipsychotic with no greater EPS than placebo across the full dose range</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1,2</NO>
<PG>154</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellewell-2000" NAME="Hellewell 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hellewell JS, Westhead E</AU>
<TI>Safety during long-term exposure to quetiapine</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97405691"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9260735"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hellewell JSE, Westhead E</AU>
<TI>Safety during long-term exposure to quetiapine</TI>
<SO>Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2033#"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-1975" NAME="Hirsch 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Hirsch SR</AU>
<TI>The interaction between depot-phenothiazines and the social and clinical manifestations of behaviour in patients with stabilised chronic schizophrenia</TI>
<SO>On the origin of schizophrenic psychoses</SO>
<YR>1975</YR>
<PG>209-22</PG>
<ED>Van Praag HM</ED>
<PB>De Erven Bohn BV</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1997-05675-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howanitz-1999" NAME="Howanitz 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Howanitz E, Pardo M, Smelson DA,Engelhart C, Eisenstein N, Losonczy MF</AU>
<TI>The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>1</NO>
<PG>41-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99173172"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10074877"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Howanitz EM, Pardo M Litwin P, Stern RG, Wainwright KM, FLosonczy M</AU>
<TI>Efficacy of clozapine versus chlorpromazine in geriatric schizophrenia</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75116103"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 235013"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakovljevic-1999" NAME="Jakovljevic 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jakovljevic M, Dossenbach MRK</AU>
<TI>Olanzapine versus fluphenazine in the acute (six-week) treatment of schizophrenia</TI>
<SO>Psychiatria Danubina</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>1-2</NO>
<PG>3-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98135874"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9477007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnstone-1997" NAME="Johnstone 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Johnstone EC, Owens DGC</AU>
<TI>Does early treatment have an effect on outcome?</TI>
<SO>10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86188455"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2870753"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Judah-1959" NAME="Judah 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Judah L, Murphree O, Seager L</AU>
<TI>Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>115</VL>
<PG>1118-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 53-05854"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-1998" NAME="Kinon 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Basson MS, Tollefson GD</AU>
<TI>Gender-specific prolactin response to treatment with olanzapine versus haloperidol in schizophrenia</TI>
<SO>Poster presented at the 9th Biennial European Winter Workshop on Schizophrenia; 1998 February 7-13, Davos, Switzerland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76179130"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 772906"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2000" NAME="Kinon 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Milton DR, Hill AL</AU>
<TI>Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<NO>Suppl 1</NO>
<PG>S154</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2001" NAME="Kinon 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Wang , Stauffer VL</AU>
<TI>A comparison of prolactin concentrations in the elderly during treatment with olanzapine, haloperidol, and risperidone</TI>
<SO>14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26; San Francisco, USA</SO>
<YR>2001</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20555729"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000420432; PMID 11106143"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2003" NAME="Kinon 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Stauffer VL, Kaiser C, Walker SK</AU>
<TI>Incidence of presumptive tardive dyskinesia in elderly patients treated with olanzapine or conventional antipsychotics</TI>
<SO>156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA</SO>
<YR>2003</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="[NR555]"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kopala-2003" NAME="Kopala 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kopala L, Rabinowitz J, Davidson M</AU>
<TI>Extra-pyramidal signs and symptoms (eps) in recent onset schizophrenia: a comparison of risperidone and haloperidol</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S338</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.2.135"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lovett-1987" NAME="Lovett 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lovett WC, Stokes DK, Taylor LB, Young ML, Free SM, Phelan DG</AU>
<TI>Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>6</NO>
<PG>234-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80146237"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 65-08548; PMID 538170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacMillan-1986" NAME="MacMillan 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacMillan JF, Crow TJ, Johnson AL, Johnstone EC</AU>
<TI>Short-term outcome in trial entrants and trial eligible patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>148</VL>
<NO>February</NO>
<PG>128-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1986102574"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McInnes-1978" NAME="McInnes 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McInnes EJ, Walker F, Snelling E</AU>
<TI>The observer interaction variable in evaluation of socialising properties of pimozide (Orap)</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1978</YR>
<VL>87</VL>
<NO>607</NO>
<PG>170-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78177644"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 349428"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-1997" NAME="Meltzer 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Meltzer H, O'Connor R</AU>
<TI>Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia</TI>
<SO>Company poster - Pfizer</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohler-1970" NAME="Mohler 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohler G</AU>
<TI>Clinical trial of thiothixene (Navane) in elderly chronic schizophrenics</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>6</NO>
<PG>377-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70214784"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4987345"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moller-1997" NAME="Moller 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moller HJ, Bauml J, Ferrero F, Fuger J, Geretsegger C, Kasper S, Kissling W, Schubert H</AU>
<TI>Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>1997</YR>
<VL>247</VL>
<NO>6</NO>
<PG>291-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98135874"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9477007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mullen-1999" NAME="Mullen 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mullen J, Bari M, Reinstein M, Sandler N, Ginsberg L</AU>
<TI>Quetiapine and risperidone in outpatients with psychoses</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<PG>254</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-10-89"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mullen J, Bari M, Reinstein M, Sandler N, Ginsberg L</AU>
<TI>Quetiapine and risperidone in outpatients with psychoses</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<PG>254</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-10-89"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mullen J, Reinstein M, Bari M, Ginsberg L, Sandler N</AU>
<TI>Quetiapine and risperidone in outpatients with psychotic disorders: results of the QUEST trial</TI>
<SO>The Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>5</NO>
<PG>S269</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0164101907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naukkarinen-2000" NAME="Naukkarinen 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naukkarinen H, Rimon R, Katila H, Riihikangas R, Heikkila L</AU>
<TI>Olanzapine and perphenazine in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niskanen-1974" NAME="Niskanen 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niskanen P, et al</AU>
<TI>Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients</TI>
<SO>Psychiatria Fennica</SO>
<YR>1974</YR>
<VL>5</VL>
<PG>307-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1977-03995-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussbaum-1964" NAME="Nussbaum 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussbaum K, Shaffer JW, Michaux WW</AU>
<TI>Modaline sulfate in the treatment of chronic schizophrenics</TI>
<SO>Journal of New Drugs</SO>
<YR>1964</YR>
<VL>4</VL>
<NO>2</NO>
<PG>86-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pigott-2003" NAME="Pigott 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG</AU>
<TI>Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64(9)</VL>
<PG>1048-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Povlsen-1987" NAME="Povlsen 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J</AU>
<TI>The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden</TI>
<TO>Neuroleptikas virkning pa tardive dyskinesier. En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol + biperiden</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1987</YR>
<VL>149</VL>
<NO>25</NO>
<PG>1682-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87265075"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3299955"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quinn-1984" NAME="Quinn 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinn N, Marsden CD</AU>
<TI>A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<NO>8</NO>
<PG>844-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87265075"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3299955"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapaport-2001" NAME="Rapaport 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapaport MH, Dolnak DR, Caligiuri M</AU>
<TI>A pilot study investigating the acute effects of olanzapine and risperidone on motor function</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1,2</NO>
<PG>242</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98135874"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9477007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reznik-1998" NAME="Reznik 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reznik I, Sirota P</AU>
<TI>Treatment of obsessive and compulsive symptoms in schizophrenia with SSRI's and neuroleptics: a randomized controlled trial</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-2003" NAME="Ritchie 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane SMM, O'Connor DW, Opie J, Ames D</AU>
<TI>The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (riperidone or olanzapine) in elderly patients with schizophrenia</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>(5)</NO>
<PG>432-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruskin-1991" NAME="Ruskin 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruskin PE, Nyman G</AU>
<TI>Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1991</YR>
<VL>179</VL>
<NO>4</NO>
<PG>212-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 78-25375"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salganik-1998" NAME="Salganik 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salganik I, Modai I, Bercovici BR, Kutzuk D, Weizman A</AU>
<TI>Clozapine vs haloperidol therapy in elderly chronic schizophrenic inpatients: preliminary results. A double blind, cross over randomized study</TI>
<SO>International Journal of Geriatric Psychopharmacology</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>4</NO>
<PG>185-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1999265614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1975" NAME="Schiele 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele BC</AU>
<TI>Loxapine succinate: a controlled double-blind study in chronic schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1975</YR>
<VL>36</VL>
<NO>7</NO>
<PG>361-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75208587"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1097221"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1991" NAME="Sharma 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma SK, Jaigirdar SH</AU>
<TI>A comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophrenia</TI>
<SO>British Journal of Clinical Research</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>177-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20570029"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11120421; EMBASE 2000441700"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silverstone-1984" NAME="Silverstone 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, Lader S, Gould S</AU>
<TI>The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1984</YR>
<VL>18</VL>
<NO>3</NO>
<PG>255-68</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85033446"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6387105"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2002" NAME="Singh 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Singh V</AU>
<TI>Ziprasidone quality of life study in the treatment of schizophrenia and schizoaffective disorder</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0163097327"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speller-1997" NAME="Speller 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speller JC, Barnes TRE, Curson DA, Pantelis C, Alberts JL</AU>
<TI>One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v haloperidol</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<NO>DECEMBER</NO>
<PG>564-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1997383387"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stotsky-1977" NAME="Stotsky 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stotsky BA</AU>
<TI>Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1977</YR>
<VL>38</VL>
<NO>12</NO>
<PG>967-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78063782"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 338270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-2001" NAME="Sutton 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sutton VK, Street JS, Kennedy JS, Feldman PD, Breier A</AU>
<TI>Superiority of olanzapine over risperidone in the control of negative symptoms of schizophrenia and related psychotic disorders in older patients</TI>
<SO>European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey)</SO>
<YR>2001</YR>
<NO>3</NO>
<PG>276</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2079#"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1972" NAME="Svestka 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Svestka J, Nahunek K</AU>
<TI>A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1972</YR>
<NO>2</NO>
<PG>93-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72225815"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4557145"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1987" NAME="Svestka 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Svestka J, Nahunek K, Rysanek R, Ceskova E, et al</AU>
<TI>Double blind comparison of isofloxythepin and haloperidol in the treatment of acute schizophrenic and schizoaffective psychoses. 29th Annual Psychopharmacology Meeting (1987, Jesenik, Czechoslovakia)</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1987</YR>
<NO>3</NO>
<PG>205-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1989-02545-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tench-1990" NAME="Tench 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tench D, Soni SD, Ashwood T, Movin G</AU>
<TI>Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1990</YR>
<VL>101</VL>
<NO>1</NO>
<PG>132-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90260098"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1971445"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tourlentes-1958" NAME="Tourlentes 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tourlentes TT, Hunsicker AL, Hurd DE</AU>
<TI>Chlorpromazine and communication process</TI>
<SO>Archives of Neurology and Psychiatry</SO>
<YR>1958</YR>
<VL>79</VL>
<PG>468-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.2.W.032"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1999" NAME="Tran 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran PV, Basson BR, Kennedy JS, Beasley Jr CM, Bymaster FP, Tollefson GD</AU>
<TI>The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S290</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98135874"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9477007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vangtorp-1968" NAME="Vangtorp 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vangtorp A, Simmelsgaard H, Mellegaard M</AU>
<TI>Experience with a new butyrophenone derivative (Buronil)</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1968</YR>
<VL>203</VL>
<PG>235-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69060493"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4881877"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasquez_x002d_Gomez-2001" NAME="Vasquez-Gomez 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vasquez-Gomez F</AU>
<TI>The use of midazolam for control of acutely agitated outpatients in psychiatry emergency</TI>
<SO>7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany</SO>
<YR>2001</YR>
<NO>Suppl. 1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="7th World Congress of Biological Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 P034-02"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vereecken-1972" NAME="Vereecken 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vereecken JL, Tanghe A</AU>
<TI>Fluspirilene and pipothiazine undecylenate, two long-acting injectable neuroleptics. A double-blind controlled trial in residual schizophrenia</TI>
<SO>Psychiatria Neurologia Neurochirurgia</SO>
<YR>1972</YR>
<VL>75</VL>
<NO>2</NO>
<PG>117-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72195113"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5030483"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vianna-1975" NAME="Vianna 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vianna Filho U, Versiani Caldeira MV, Bueno J</AU>
<TI>Preliminary report on a double blind study comparing loxapine succinate with thiothixene in chronic schizophrenic patients</TI>
<SO>Jornal Brasileiro de Psiquiatria</SO>
<YR>1975</YR>
<VL>24</VL>
<NO>1</NO>
<PG>5-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 56-08467"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vianna Filho U, Versiani Caldeira MV, Romildo Bueno J</AU>
<TI>The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>3</NO>
<PG>476-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-1983" NAME="Walker 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker CA</AU>
<TI>A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out- patients</TI>
<SO>Pharmatherapeutica</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>5</NO>
<PG>289-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83195220"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6133287"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetzel-1991" NAME="Wetzel 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetzel H, von Bardeleben U, Holsboer F, Benkert O</AU>
<TI>Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness</TI>
<TO>Zotepin versus Perazin bei Patienten mit paranoider schizophrenie: eine doppelblind-kontrollierte Wirksamkeitsprufung</TO>
<SO>Fortschritte der Neurologie-Psychiatrie</SO>
<YR>1991</YR>
<VL>59</VL>
<NO>Suppl 1</NO>
<PG>23-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92064289"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1683336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woggon-1978" NAME="Woggon 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woggon B, Angst J</AU>
<TI>Double-blind comparison of bromperidol and perphenazine</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1978</YR>
<VL>13</VL>
<NO>3</NO>
<PG>165-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78241397"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 355182"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woggon B</AU>
<TI>Effects and side-effects of bromperidol in comparison with other antipsychotic drugs</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1978</YR>
<VL>78</VL>
<NO>1</NO>
<PG>155-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78162829"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 347878"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodruff-2002" NAME="Woodruff 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Woodruff P</AU>
<TI>A phase IIIb, 12 week, multi-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone (40-80mg bid) versus olanzapine (5-20mg od) on the quality of life in the treatment of chronic schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0164101907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamawaki-1996" NAME="Yamawaki 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yamawaki S, Hayashi T, Yokota N, Takahashi T, Sato G, Tahara Y</AU>
<TI>Serotonin-dopamine antagonists in elderly schizophrenics</TI>
<SO>20th Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1996 Jun 23-27; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67129859"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6021696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" NAME="Chen 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Chang-yun, Chen Wei-xiang, MAO Li</AU>
<TI>Nursing about side effects of old psychotic disease patients when taking medicine</TI>
<SO>Journal of Qilu Nursing</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>01</NO>
<PG>11-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0304"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2002" NAME="Lin 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LIN Jianrong, HUANG Yukun, CHEN Guozhong, et al</AU>
<TI>A control study of treating elderly patients with schizophrenia with quetiapine or perphenazine</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>02</NO>
<PG>99-102</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0209"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vencovsky-1975" NAME="Vencovsky 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vencovsky E, Peterova E, Baudis P</AU>
<TI>Comparison of therapeutic effect of clozapin and chlorpromazin (author's transl)</TI>
<TO>Srovnani terapeutickeho ucinku clozapinu s chlorpromazinem</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1975</YR>
<VL>71</VL>
<NO>1</NO>
<PG>21-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75166821"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1093729"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" NAME="Wang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Jian, XIE Shiping</AU>
<TI>Health economic impact of novel versus older anti-psychotic medications in schizophrenia.</TI>
<SO>Sichuan Mental Health</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>01</NO>
<PG>8-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacro-2001" NAME="Lacro 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Lacro J</AU>
<TI>Antipsychotic treatment in late life schizophrenia</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html accessed 19th February 2001)</SO>
<YR>2001</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CRISP Grant Number - 5R29MH56938-04"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matkovits_x002d_Gupta-1999" NAME="Matkovits-Gupta 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Matkovits-Gupta T//Lasser R//Young F//Happy J//Gharabawi G//Cucchiaro J//Fairweather D</AU>
<TI>Managing psychotic disorders through balanced receptor blockade: the zomaril tm clinical program</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<PG>163</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th World Congress of Psychiatry [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1999 PO-12-31"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2001" NAME="Newcomer 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Newcomer JW</AU>
<TI>Neurochemical control of memory in aging schizophrenics</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html accessed 19th February 2001)</SO>
<YR>2001</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CRISP Grant Number - 5K02MH01510-04"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-21 13:59:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-21 13:59:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="OLZ020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arunpongpaisal-2003" MODIFIED="2008-10-21 13:57:48 +0100" MODIFIED_BY="[Empty name]" NAME="Arunpongpaisal 2003" TYPE="COCHRANE_REVIEW">
<AU>Arunpongpaisal S, Ahmed I, Aqeel N, Paholpak S</AU>
<TI>Antipsychotic drug treatment for elderly people with late-onset schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-21 13:57:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 13:57:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TRE</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bleuler-1974" NAME="Bleuler 1974" TYPE="JOURNAL_ARTICLE">
<AU>Bleuler M</AU>
<TI>The long term course of the schizophrenic psychoses</TI>
<SO>Psychological Medicine</SO>
<YR>1974</YR>
<VL>4</VL>
<NO>3</NO>
<PG>244-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2005" NAME="Cates 2005" TYPE="OTHER">
<AU>Cates C</AU>
<TI>Dr Chris Cates' EBM web site - Visual Rx</TI>
<SO>http://www.nntonline.net/</SO>
<YR>Accessed 8th November 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The Extrapyramidal Symptom Rating Scale</TI>
<SO>Canadian Journal of Neurological Science</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciompi-1980" NAME="Ciompi 1980" TYPE="JOURNAL_ARTICLE">
<AU>Ciompi L</AU>
<TI>The natural history of schizophrenia in the long term</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>136</VL>
<PG>413-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornblatt-1989" NAME="Cornblatt 1989" TYPE="JOURNAL_ARTICLE">
<AU>Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L</AU>
<TI>The continuous performance test, identical pairs version:II. Contrasting attentional profiles in schizophrenic and depressed patients</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>29</VL>
<PG>65-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czobor-1995" NAME="Czobor 1995" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J &amp; Meibach RC</AU>
<TI>Effect of risperidone on hostility in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>4</NO>
<PG>243-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2000" NAME="Davidson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Harvey PD, Vervarcke J et al</AU>
<TI>A long-term, multicentre,open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>6</NO>
<PG>506-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devanand-1998" NAME="Devanand 1998" TYPE="JOURNAL_ARTICLE">
<AU>Devanand D P, Marder K, Michaels K S et al</AU>
<TI>A randomised, placebo-controlled dose comparison trial of haloperidol for psychosis and disruptive behaviours in Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>November</NO>
<PG>1512-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2005" NAME="FDA 2005" TYPE="OTHER">
<AU>Food and Drugs Administration</AU>
<TI>Alert for Healthcare Professionals - Risperidone (marketed as Risperdal)</TI>
<SO>http://www.fda.gov/cder/drug/InfoSheets/HCP/risperidoneHCP.htm)</SO>
<YR>Accessed 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frenchman-1997" NAME="Frenchman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Frenchman I B &amp; Prince T</AU>
<TI>Clinical experience with risperidone, haloperidol and thioridazine for dementia-associated behavioural disturbances</TI>
<SO>International Journal of Psychogeriatrics</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>4</NO>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338</SO>
<YR>1976</YR>
<PG>217-22</PG>
<PB>US Department of Health, Education and Welfare</PB>
<CY>Rockville, Md, US</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heaton-1993" NAME="Heaton 1993" TYPE="BOOK">
<AU>Heaton RK, Chelune CJ, Talley JL, Kay GG, Curtiss G</AU>
<SO>Wisconsin card sorting test manual-revised and expanded</SO>
<YR>1993</YR>
<PB>Psychological assessment resources.</PB>
<CY>Odessa, FL</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-10-21 13:59:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>3</NO>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-2000" NAME="Howard 2000" TYPE="JOURNAL_ARTICLE">
<AU>Howard R, Rabins PV, Seeman MV &amp; Jeste DV</AU>
<TI>Late-onset schizophrenia and very late-onset shizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<PG>172-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huber-1975" NAME="Huber 1975" TYPE="JOURNAL_ARTICLE">
<AU>Huber G, Gross G &amp; Schuttler R</AU>
<TI>A long term follow up study of schizophrenia: psychiatric course of illness and prognosis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1975</YR>
<VL>52</VL>
<NO>1</NO>
<PG>49-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1986" NAME="Jablensky 1986" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A</AU>
<TI>Epidemiology of schizophrenia: a European perspective</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>1</NO>
<PG>52-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jayaram-2005" MODIFIED="2008-10-21 13:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Jayaram 2005" TYPE="COCHRANE_REVIEW">
<AU>Jayaram MB, Hosalli P</AU>
<TI>Risperidone versus olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005237."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Katz-1999" NAME="Katz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Katz I R, Jeste D V, Minter J E &amp; the risperidone study group</AU>
<TI>Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomised, double-blind trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>2</NO>
<PG>107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay S, Fiszbein A, Opler LA</AU>
<TI>The Positive and Negative Syndrome Scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1994" NAME="Kerwin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin RW</AU>
<TI>The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>164</VL>
<PG>141-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1994" NAME="Kessler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, McGonagle K A, Zhao S et al</AU>
<TI>Lifetime and 12-month Prevalence of DSM III R psychiatric disorders in the United States: results from the National Comorbidity Survey</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>1</NO>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lezak-1997" NAME="Lezak 1997" TYPE="BOOK">
<AU>Lezak MD</AU>
<SO>Neuropsychological assessment</SO>
<YR>1997</YR>
<EN>3rd</EN>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martindale-1999" NAME="Martindale 1999" TYPE="BOOK">
<AU>Ed K Parsitt</AU>
<SO>The complete drug reference</SO>
<YR>1999</YR>
<EN>32nd edition</EN>
<PB>Pharmaceutical Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-1989" NAME="Morris 1989" TYPE="JOURNAL_ARTICLE">
<AU>Morris JC, Heyman A, Mohs RC</AU>
<TI>The consortium to establish a registry for alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39</VL>
<PG>1159-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naguib-1995" NAME="Naguib 1995" TYPE="BOOK_SECTION">
<AU>Naguib M, Levy R</AU>
<TI>Paranoid states in the elderly and late paraphrenia</TI>
<SO>Psychiatry in the elderly</SO>
<YR>1995</YR>
<PG>758-78</PG>
<ED>Jacoby R, Oppenheimer C</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall LE, Gogham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regier-1988" NAME="Regier 1988" TYPE="JOURNAL_ARTICLE">
<AU>Regier D A, Boyd J H, Burke J D et al</AU>
<TI>One month prevalence of mental disorders in the United States</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>11</NO>
<PG>977-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sajatovic-2000" NAME="Sajatovic 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sajatovic M, Madhusoodanan S &amp; Buckley P</AU>
<TI>Schizophrenia in the elderly: Guidelined for management</TI>
<SO>CNS Drugs</SO>
<YR>2000</YR>
<VL>64</VL>
<NO>2</NO>
<PG>134-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seeman-1987" NAME="Seeman 1987" TYPE="JOURNAL_ARTICLE">
<AU>Seeman P</AU>
<TI>Dopamine receptors and the dopamine hypothesis of schizophrenia</TI>
<SO>Synapse</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>2</NO>
<PG>133-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>1970</YR>
<VL>supplement 212</VL>
<PG>11-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spreen-1998" NAME="Spreen 1998" TYPE="BOOK">
<AU>Spreen O, Strauss JS</AU>
<SO>A compendium of neuropsychological tests and norms</SO>
<YR>1998</YR>
<EN>2nd</EN>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tariot-1993" NAME="Tariot 1993" TYPE="JOURNAL_ARTICLE">
<AU>Tariot PN, Podgorski CA, Blazina L</AU>
<TI>Mental disorders in the nursing home: another perspective</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<PG>1063-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UK-ONS-2003" NAME="UK ONS 2003" TYPE="OTHER">
<AU>UK Office of National Statistics</AU>
<TI>UK Census</TI>
<SO>www.staistics.gov.uk</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-UN-Popin-2003" NAME="UN Popin 2003" TYPE="OTHER">
<TI>United Nations Population Information Network</TI>
<SO>www.un.org./popin/data</SO>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Harvey_x002f_Jeste-2003">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks, preceded by a 1 week wash-out period.<BR/>Design: multicentre. <BR/>Setting: hospital and community including nursing home residents and board and care patients, North America.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia and schizoaffective disorder (DSM-IV).<BR/>N=175.<BR/>Consent: described.<BR/>Age: over 60, mean 71 years. <BR/>Sex: M 62, F 113.<BR/>History: not reported.<BR/>Exclusions: DSM-IV diagnosis of substance abuse or dependence during the previous 3 months; major depressive episode as defined by DSM-IV criteria within 6 months before screening; MMSE score of less than 18; major disorder of the central nervous system (incl. dementia); history of neuroleptic malignant syndrome; QTc interval of &gt;500msec; any acute unstable, significant, or untreated medical illness; patients judged to be unresponsive to risperidone or olanzapine; renal, hepatic, or gastrointestinal disease that could potentially interfere with the absorption, excretion or metabolism of trial medications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: dose range 1-3 mg/day (mean 1.9 mg/day). N=87.<BR/>2. Olanzapine: dose range 5-20 mg/day (mean 11.1 mg/day). N=88.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Cognitive function: CPT, SVLT, TMT(A+B), WCST, VFE.<BR/>Mental state: PANSS (positive, negative).<BR/>Global state: CGI.<BR/>Adverse events: ESRS.<BR/>Death.</P>
<P>Unable to use -<BR/>Cognitive function: MMSE (data incomplete).<BR/>Mental state: Ham-D (data incomplete), ACS (scale not published in peer review journal).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Concomitant medications disallowed during the study period included antidepressants, anticonvulsants, mood stabilizers other antipsychotics, sedatives, anxiolytics, and other psychoactive drugs (except lorazepam during washout period, for agitation).<BR/>Results reported in two main groups - mental state and side-effect data (Jeste et al): cognitive function data (Harvey et al).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Phanjoo-1990">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks, preceded by a 2-5 day wash-out period. Depot neuroleptics were stopped at least one dose interval before the start of active medication.<BR/>Design: parallel, single centre. <BR/>Setting: hospital in-patients including nursing home residents and board and care patients, North America.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, paranoia, acute paranoid disorder, atypical paranoid disorder (DSM-IV).<BR/>Consent: described.<BR/>N=18.<BR/>Age: over 65, range 66-95 years. <BR/>Sex: M 1, F 17.<BR/>History: diagnosis as above and considered to be in need of antipsychotic treatment.<BR/>Exclusions: alcohol/drug dependence; major depressive episode; severe dementia; serious somatic illness, including renal or hepatic insufficiency; illnesses associated with abnormal involuntary movements; history of allergic or toxic reaction to drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Remoxipride: dose 200 mg/day (mean and max dose). N=9.<BR/>2. Thioridazine: dose mean 133 mg/day, max 200 mg/day. N=9.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no SD), NOSIE (no SD), CVAS (no SD).<BR/>Cognitive function: GBS (no data).<BR/>Global state: CGI (no SD).<BR/>Adverse events: AIMS (no SD), SAS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Concomitant medications disallowed during the study period included antidepressants and other antipsychotics. Chloral hydrate or a short acting benzodiazepine could be given as a hypnotic at night. In the event of intolerable extrapyramidal symptoms an anticholinergic could be given and procyclidine was recommended. Non-psychotropic medication could be given at the investigators discretion.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tollefson-1997">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks, preceded by 2-9 day screening period after which eligable patients were included.<BR/>Design: multicentre. <BR/>Setting: hospital and community, Europe and North America.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, schizoaffective disorder and schizophreniform psychosis (DSM-III-R).<BR/>Consent: described.<BR/>N=59*.<BR/>Age: &gt;18, of whom 59 were 65 years or older, mean 69 years. <BR/>Sex: male and female, numbers not specified.<BR/>History: minimum BPRS score of 18 and/or intolerant of current antipsychotic, excluding haloperidol.<BR/>Exclusions: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine: dose range 5-20 mg/day (mean 12.4 mg/day). N=44.<BR/>2. Haloperidol: dose range 5-20 mg/day (mean 8.7 mg/day). N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS (total), MADRS, PANSS (total), PANSS (positive), PANSS (negative)<BR/>Adverse events: AIMS, BAS, SAS, dry mouth, constipation.</P>
<P>Unable to use -<BR/>Adverse events: akathisia (no SD), back pain (no data), rhinitis (no data), tremor (no SD), weight gain (endpoint data only).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*subset of N=1998.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tools<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4</P>
<P>Rating Scales:</P>
<P>Cognitive function -<BR/>CPT - Continuous performance test<BR/>GBS - Gotheries, Brane &amp; Steen (rating scale for dementia)<BR/>MMSE - Mini mental state examination<BR/>SVLT - Serial verbal learning test<BR/>TMT - Trail making test<BR/>VFE - Verbal fluency examination<BR/>WCST - Wisconsin card sorting test</P>
<P>Global rating scales -<BR/>CGI - Clinical Global Impressions</P>
<P>Mental state -<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>CVAS - Crichton visual analogue scale<BR/>Ham-D - Hamilton depression scale<BR/>MADRS - Montgomery-Asberg Depression Rating Scale<BR/>NOSIE - Nurses observation scale for in-patient evaluation<BR/>PANSS - Positive and Negative Syndrome Scale</P>
<P>
<BR/>Side effects -<BR/>ACS - Anticholinergic symptom survey<BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>BAS - Barnes Akathisia Scale<BR/>BMI - Body mass index<BR/>ESRS - Extrapyramidal Syndrome Rating Scale<BR/>SAS - Simpson-Angus Index - for neurological side effects</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Altman-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt;80% were over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andia-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt; 80% were over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Angst-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt; 80% were over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ayers-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Azorin-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and poor response to previous treatment, age range 18-65 yrs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baldini-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and depressive symptoms, age range 17-82 yrs.<BR/>Interventions: amitriptyline-fluphenazine combination versus placebo (not antipsychotic alone).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bamrah-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with dementia and psychosis (not schizophrenia).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barak-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone versus typical antipsychotics.<BR/>Outcomes: no usable data (unable to obtain further details from authors).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barak-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia age range 63-83; mean age quoted differently in abstract, 72.7 (sd 5.9), and methods, 69.2 (sd 6.1); assuming a normal distribution, the abstract figure would suggest that 80% of participants were over 65 years, whereas the methods figure would not support this; we were unable to contact the author to clarify this.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bateman-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised<BR/>Participants: people with tardive dyskinesia secondary to long term neuroleptics.<BR/>Interventions: treatment for tardive dyskinesia not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beasley-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder, age range 18-65 yrs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berman-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 57-77 yrs, (proportion over 65 not stated, no information provided by authors).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bora-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 50-80 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bossie-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder, participants &lt;65 years of age.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brauzer-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breier-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt; 80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buruma-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with tardive dyskinesia and underlying psychiatric syndromes, age range 39-70 years (not clear if diagnosis is schizophrenia).<BR/>Interventions: tiapride and placebo (studied with respect to their effect on tardive dyskinesia, not as a treatment for schizophrenia).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cantillon-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age not stated (unclear if 80% over 65, no information provided by the authors).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Canuso-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cassano-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 19-75 yrs (mean 38 yrs, &lt; 80% over 65).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised within blocks.<BR/>Participants: people with schizophrenia; no information regarding age.<BR/>Interventions: alpha-methyldopa versus rubidium versus tryptophan-benserazide with chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-57 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Citrome-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and schizoaffective disorder, age range 18-60 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cody-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, aged over 14.<BR/>Interventions: various antipsychotic medications offered at nominal cost versus full price, no further details.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Conley-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and schizoaffective disorder, age range 18-64 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coryell-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age over 17 years (mean 32).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crow-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with first episode schizophrenia, age over 59 years, no further details.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Csernansky-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and schizoaffective disorder, age range 18-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daniel-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and schizoaffective disorder, age range 18-67 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Jong-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 35-75 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delwaide-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with bucco-lingual-facial dyskinesias.<BR/>Interventions: thioperazine, tiapride and placebo; given to treat dyskinesia not as a treatment for schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denijs-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 26-80 years, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dick-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 20-66 years, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Docherty-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder, age "elderly", no further details - not clear if 80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dolnak-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age 18-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ekblom-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 15-60 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elie-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age over 60 years, no further details.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emsley-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age not stated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emsley-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-75 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evans-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with alzheimer's disease and psychosis (not schizophrenia).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feldman-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age 50-65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fitzgerald-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with psychosis (unclear if &gt;80% with diagnosis of schizophrenia), age range 22-68 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Friedman-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garry-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 23-72 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerlach-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with tardive dyskinesia - antipsychotics given to investigate their effects on TD, not given as a treatment for schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glazer-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and tardive dyskinesia (TD) whose TD worsened on withdrawal of usual medication.<BR/>Interventions: molindone or haloperidol given to investigate their effects on TD - not given as a treatment for schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glazer-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and tardive dyskinesia, age range 18-70 years.<BR/>Interventions: molindone and haloperidol given to mask tardive dyskinesia - not as a treatment for schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glazer-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age over 18 years, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gregor-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age unclear &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gross-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 21-67 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haggstrom-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanlon-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 21-74 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised ("where possible").<BR/>Participants: peoples with dementia, schizophrenia, mood disorders and other conditions &lt;80% with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and related disorders, age over 45 years, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harvey-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder, age not stated (later correspondence reveals 'insignificant numbers over 65').</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harvey-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder, age range 18-64 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harvey-2004a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder, age range 18-55 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harvey-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heck-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 23-68 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hellewell-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age not stated, unclear if 80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hellewell-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: unknown number of participants with schizophrenia, age not stated, not clear if 80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hellewell-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: open label extension of a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hirsch-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age under 67, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Howanitz-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age at least 55 yrs, not clear if 80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jakovljevic-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnstone-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 15-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Judah-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or other diagnosis, median age 63 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 23-72 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 23-72 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age mean 69 yrs, not clear if 80% over 65 and unable to contact authors for clarification.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: elderly people with schizophrenia - no further details, unable to contact authors for clarification.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kopala-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age not specified, no further details, unable to contact authors for clarification.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lovett-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic brain syndromes (unclear how many might have schizophrenia or related disorders and unable to contact authors for separate information on participants with schizophrenia or related disorders); age over 60 (unclear if 80% over 65 and unable to contact authors for separate information on older participants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacMillan-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 15-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McInnes-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meltzer-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mohler-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moller-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 20-68 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mullen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age reported as 'including elderly over 65 years', &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naukkarinen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-70 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niskanen-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 15-60 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussbaum-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-70 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pigott-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-77 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Povlsen-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with tardive dyskinesia, age range 47-80 years.<BR/>Interventions: treatments for TD not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quinn-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with Huntington's disease or tardive dyskinesia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rapaport-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reznik-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia plus obsessional symptoms, age range 27-67 years.<BR/>Intervention: neuroleptic + fluvoxamine versus neuroleptic alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ritchie-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age over 60, mean 69 (sd 6.2), assuming a normal distribution &lt;80% are over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruskin-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age over 50 yrs, mean age 60, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salganik-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 60-78 yrs, mean 66.6 (sd 5.08), assuming a normal distribution &lt;80% are over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schiele-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 29-74 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharma-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 30-81 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silverstone-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 19-68 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singh-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Trial withdrawn because ziprasidone had not been granted a licence in the UK in time.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Speller-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 35-76 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stotsky-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia (80%), age range 18-66 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutton-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: 39 patients with schizophrenia, age range 50-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, paraphrenia and schizoaffective disorder, age range 17-81 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not stated.<BR/>Participants: people with schizophrenia/schizoaffective disorder/paraphrenia, age range 18-56 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tench-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-70 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tourlentes-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 45-74 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tran-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-65 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vangtorp-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia, senile psychoses (unclear if 80% with schizophrenia or related psychoses), age not stated, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vasquez_x002d_Gomez-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or affective psychosis (unclear if &gt;80% with schizophrenia or related psychoses), age range 18-83 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vereecken-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 22-75 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vianna-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: probably randomised.<BR/>Participants: people with schizophrenia, age 16 and over, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walker-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 23-67 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wetzel-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-68 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woggon-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, age range 18-68 yrs, &lt;80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woodruff-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Trial withdrawn because ziprasidone had not been granted a licence in the UK.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yamawaki-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: unclear - 35 people with schizophrenia in treatment arm, age unclear - described as elderly, unclear if 80% over 65.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Chen-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lin-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Vencovsky-1975">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wang-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Lacro-2001">
<CHAR_STUDY_NAME>
<P>Antipsychotic treatment in late life schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Older patients with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Haloperidol vs Risperidone for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical response<BR/>Cognitive performance<BR/>Health related quality of life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not stated</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Matkovits_x002d_Gupta-1999">
<CHAR_STUDY_NAME>
<P>Managing psychotic disorders through balance receptor blockade: the Zomaril tm clinical programme</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients with psychotic disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Iloperidone vs placebo and/or active control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PANS scale;Clinical Global Impression of Improvement;Clagary Depression Scale;Psychotic Anxiety Scale;Cognitive functioning tests and quality of life scales</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not stated</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Newcomer-2001">
<CHAR_STUDY_NAME>
<P>Neurochemical control of memory in aging schizophrenics</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Older patients with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not stated</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not stated</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Harvey_x002f_Jeste-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Phanjoo-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>THIORIDAZINE versus REMOXIPRIDE (all short term data)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.643801456189747" CI_START="0.0732933561962918" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.1349353909531412" LOG_CI_START="-1.1349353909531412" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Thioridazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Remoxipride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours thioridazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours remoxipride</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.643801456189747" CI_START="0.0732933561962918" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1349353909531412" LOG_CI_START="-1.1349353909531412" LOG_EFFECT_SIZE="0.0" ORDER="139" O_E="0.0" SE="1.3333333333333333" STUDY_ID="STD-Phanjoo-1990" TOTAL_1="9" TOTAL_2="9" VAR="1.7777777777777777" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>RISPERIDONE versus OLANZAPINE (all short term data)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.16375196925498" CI_START="0.013921382238226794" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3371212121212121" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.9118898015290604" LOG_CI_START="-1.856317641978897" LOG_EFFECT_SIZE="-0.47221392022491826" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5036997247284543" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="88" WEIGHT="100.0" Z="0.6686798554854401">
<NAME>Death: Suicide and natural causes</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.16375196925498" CI_START="0.013921382238226794" EFFECT_SIZE="0.3371212121212121" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9118898015290604" LOG_CI_START="-1.856317641978897" LOG_EFFECT_SIZE="-0.47221392022491826" ORDER="140" O_E="0.0" SE="1.6260587551644161" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="87" TOTAL_2="88" VAR="2.6440670752468507" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9361198746317678" CI_START="0.8253793671579126" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2641334569045413" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.28693224309602766" LOG_CI_START="-0.08334639182092876" LOG_EFFECT_SIZE="0.10179292563754944" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.28120185377067175" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.00000000000001" Z="1.0776234398471611">
<NAME>Global state: Not improved or worse (CGI)</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9361198746317678" CI_START="0.8253793671579126" DF="0.0" EFFECT_SIZE="1.2641334569045413" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.28693224309602766" LOG_CI_START="-0.08334639182092876" LOG_EFFECT_SIZE="0.10179292563754944" NO="1" P_CHI2="1.0" P_Z="0.28120185377067175" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.00000000000001" Z="1.0776234398471611">
<NAME>Sub-category</NAME>
<DICH_DATA CI_END="1.9361198746317678" CI_START="0.8253793671579126" EFFECT_SIZE="1.2641334569045413" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.28693224309602766" LOG_CI_START="-0.08334639182092876" LOG_EFFECT_SIZE="0.10179292563754944" ORDER="141" O_E="0.0" SE="0.21750350305902383" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="83" TOTAL_2="88" VAR="0.04730777384294679" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2603311199463718" CI_START="0.7599767167462219" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9786839666357738" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.10048465993783129" LOG_CI_START="-0.11919971290806577" LOG_EFFECT_SIZE="-0.00935752648511723" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8673931882976611" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0" Z="0.1669705920145243">
<NAME>Mental state: 1. Not improved (PANSS decrease of less than 20%)</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2603311199463718" CI_START="0.7599767167462219" EFFECT_SIZE="0.9786839666357738" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.10048465993783129" LOG_CI_START="-0.11919971290806577" LOG_EFFECT_SIZE="-0.00935752648511723" ORDER="142" O_E="0.0" SE="0.12904368806486374" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="83" TOTAL_2="88" VAR="0.01665227342938186" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.12571573450591442" CI_END="1.2926092786847487" CI_START="-1.3895649553822054" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04847783834872842" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.9390769455493678" P_Q="0.9390769455493678" P_Z="0.9435178526710568" Q="0.12571573450591442" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="249" TOTAL_2="264" UNITS="" WEIGHT="300.0" Z="0.0708491014528854">
<NAME>Mental state: 2. Average endpoint score (PANSS, high = poor)</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.44523321060166" CI_START="-5.44523321060166" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0" Z="0.0">
<NAME>total</NAME>
<CONT_DATA CI_END="5.44523321060166" CI_START="-5.44523321060166" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="65.0" ORDER="143" SD_1="18.8" SD_2="17.45" SE="2.7782312601420047" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1631853358047515" CI_START="-1.7631853358047527" DF="0.0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="1.0" P_Z="0.8417372512873407" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0" Z="0.19967182402945322">
<NAME>positive</NAME>
<CONT_DATA CI_END="2.1631853358047515" CI_START="-1.7631853358047527" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="18.3" MEAN_2="18.1" ORDER="144" SD_1="7.11" SD_2="5.89" SE="1.00164357676473" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6505966044450457" CI_START="-2.250596604445047" DF="0.0" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.03" NO="3" P_CHI2="1.0" P_Z="0.7630784671227447" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0" Z="0.3014406946172775">
<NAME>negative</NAME>
<CONT_DATA CI_END="1.650596604445046" CI_START="-2.2505966044450476" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="17.5" ORDER="145" SD_1="6.48" SD_2="6.53" SE="0.995220636619399" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4654284634279877" CI_START="0.8271020059599465" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4279918864097363" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.39189240561418287" LOG_CI_START="-0.08244092588441844" LOG_EFFECT_SIZE="0.1547257398648822" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.20101483346683535" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="88" WEIGHT="100.0" Z="1.2786656870955175">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4654284634279877" CI_START="0.8271020059599465" EFFECT_SIZE="1.4279918864097363" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.39189240561418287" LOG_CI_START="-0.08244092588441844" LOG_EFFECT_SIZE="0.1547257398648822" ORDER="146" O_E="0.0" SE="0.27862574691013714" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="87" TOTAL_2="88" VAR="0.07763230684123179" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.24566977130053" CI_END="0.14376444377138603" CI_START="-0.239001825349359" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.047618690788986485" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.751086287344571" P_Q="0.751086287344571" P_Z="0.6257869166340322" Q="4.24566977130053" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="535" TOTAL_2="549" UNITS="" WEIGHT="800.0" Z="0.48766532720740424">
<NAME>Cognitive function</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10151867775798776" CI_START="-0.38151867775798776" DF="0.0" EFFECT_SIZE="-0.14" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" NO="1" P_CHI2="1.0" P_Z="0.25590505192421764" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="50" WEIGHT="100.0" Z="1.1361231370708451">
<NAME>attention domain - Continuous Performance Test</NAME>
<CONT_DATA CI_END="0.10151867775798776" CI_START="-0.38151867775798776" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.14" ORDER="147" SD_1="0.51" SD_2="0.72" SE="0.12322607949077446" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="54" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.519452666976877" CI_START="-13.699452666976876" DF="0.0" EFFECT_SIZE="-0.5899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="1.0" P_Z="0.9297101373925009" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="76" WEIGHT="100.0" Z="0.08820953706111516">
<NAME>attention domain - Trail Making Part A</NAME>
<CONT_DATA CI_END="12.519452666976877" CI_START="-13.699452666976876" EFFECT_SIZE="-0.5899999999999999" ESTIMABLE="YES" MEAN_1="-20.71" MEAN_2="-20.12" ORDER="148" SD_1="52.54" SD_2="21.1" SE="6.688619163608395" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="71" TOTAL_2="76" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.132389590070108" CI_START="-26.95238959007011" DF="0.0" EFFECT_SIZE="-8.41" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.03" NO="3" P_CHI2="1.0" P_Z="0.37402880568154573" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="72" WEIGHT="100.0" Z="0.8889521509573423">
<NAME>executive domain - Trail Making Part B</NAME>
<CONT_DATA CI_END="10.132389590070108" CI_START="-26.95238959007011" EFFECT_SIZE="-8.41" ESTIMABLE="YES" MEAN_1="-14.74" MEAN_2="-6.33" ORDER="149" SD_1="52.23" SD_2="59.98" SE="9.460576692393387" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="69" TOTAL_2="72" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.724092294673566E-33" CI_END="0.4957392687245575" CI_START="-0.2957392687245574" DF="0.0" EFFECT_SIZE="0.10000000000000002" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-002.06.04" NO="4" P_CHI2="0.0" P_Z="0.6204120238270512" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.49526648969077397">
<NAME>executive domain - WCST categories</NAME>
<CONT_DATA CI_END="0.4957392687245574" CI_START="-0.29573926872455747" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.0" ORDER="150" SD_1="1.4" SD_2="0.78" SE="0.20191150033679103" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2543717758288526" CI_START="-10.114371775828854" DF="0.0" EFFECT_SIZE="-3.9300000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.05" NO="5" P_CHI2="1.0" P_Z="0.2129466488541586" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0" Z="1.245503785743876">
<NAME>executive domain - WCST total errors</NAME>
<CONT_DATA CI_END="2.2543717758288526" CI_START="-10.114371775828854" EFFECT_SIZE="-3.9300000000000006" ESTIMABLE="YES" MEAN_1="-4.94" MEAN_2="-1.01" ORDER="151" SD_1="16.49" SD_2="18.85" SE="3.1553497026529" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.6672144796845664E-33" CI_END="3.965146711672907" CI_START="-2.4051467116729075" DF="0.0" EFFECT_SIZE="0.7799999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-002.06.06" NO="6" P_CHI2="0.0" P_Z="0.6312493874401328" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="0.47996907091865104">
<NAME>executive domain - verbal fluency - total production</NAME>
<CONT_DATA CI_END="3.965146711672907" CI_START="-2.4051467116729075" EFFECT_SIZE="0.7799999999999998" ESTIMABLE="YES" MEAN_1="2.92" MEAN_2="2.14" ORDER="152" SD_1="9.94" SD_2="9.68" SE="1.6251047145748279" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6743125136613264" CI_START="-0.45431251366132663" DF="0.0" EFFECT_SIZE="0.10999999999999988" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.07" NO="7" P_CHI2="1.0" P_Z="0.7024236971602011" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.3820507840604013">
<NAME>memory domain - delayed recall</NAME>
<CONT_DATA CI_END="0.6743125136613264" CI_START="-0.45431251366132663" EFFECT_SIZE="0.10999999999999988" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.02" ORDER="153" SD_1="1.89" SD_2="1.58" SE="0.2879198383809864" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7549893288391842" CI_START="-1.0749893288391845" DF="0.0" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.08" NO="8" P_CHI2="1.0" P_Z="0.6376771843491191" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.4709489613538662">
<NAME>memory domain - Serial Verbal Test - total learning</NAME>
<CONT_DATA CI_END="1.7549893288391842" CI_START="-1.0749893288391845" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" MEAN_1="2.73" MEAN_2="2.39" ORDER="154" SD_1="4.7" SD_2="4.01" SE="0.7219465969785361" STUDY_ID="STD-Harvey_x002f_Jeste-2003" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>OLANZAPINE versus HALOPERIDOL (all short term data)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.6378517374356" CI_START="-10.8378517374356" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3296312167132235" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.9748569879996075">
<NAME>Mental state: 1. Average change score (BPRS, decline = good)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.637851737435601" CI_START="-10.8378517374356" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" MEAN_1="-13.5" MEAN_2="-9.9" ORDER="155" SD_1="12.5" SD_2="12.3" SE="3.69284935566513" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2238974350185226" CI_END="1.2847545049471487" CI_START="-3.4692705034830587" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0922579992679549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.5422933463947075" P_Q="0.5422933463947075" P_Z="0.3677901075168565" Q="1.2238974350185226" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="0.9006205632468317">
<NAME>Mental state: 2. Average change score (PANSS, high = poor)</NAME>
<GROUP_LABEL_1>olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.30555794235066" CI_START="-18.30555794235066" DF="0.0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.3392500289863326" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="0.9556481682775224">
<NAME>total</NAME>
<CONT_DATA CI_END="6.30555794235066" CI_START="-18.30555794235066" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-21.5" MEAN_2="-15.5" ORDER="156" SD_1="20.7" SD_2="21.1" SE="6.278461257153361" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.342786512803945" CI_START="-3.342786512803945" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>positive</NAME>
<CONT_DATA CI_END="3.342786512803945" CI_START="-3.342786512803945" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-5.4" ORDER="157" SD_1="6.0" SD_2="5.6" SE="1.7055346624588095" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6160365373602144" CI_START="-5.416036537360215" DF="0.0" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="1.0" P_Z="0.28954165755912276" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="1.0591276657841484">
<NAME>negative</NAME>
<CONT_DATA CI_END="1.616036537360214" CI_START="-5.416036537360215" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-3.3" ORDER="158" SD_1="6.0" SD_2="6.0" SE="1.7939291563999449" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8960942409288313" CI_START="-10.29609424092883" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0997394941667268" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.6461178691317553">
<NAME>Mental state: 3. Not improved (MADRS decrease of less than 50%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8960942409288313" CI_START="-10.29609424092883" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-3.5" ORDER="159" SD_1="9.4" SD_2="9.6" SE="2.8552025879404455" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4595094652991347" CI_END="-0.2890982449421513" CI_START="-1.76571417574682" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0274062103444856" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.4820272851839251" P_Q="0.4820272851839251" P_Z="0.0063830879819360515" Q="1.4595094652991347" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="2.7274244138360864">
<NAME>Adverse events: 1. Average change scores (decline = good)</NAME>
<GROUP_LABEL_1>olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2077430405904851" CI_START="-1.792256959409515" DF="0.0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.0133647339291501" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="2.4738993596229877">
<NAME>akathisia (Barnes Akathisia Scale)</NAME>
<CONT_DATA CI_END="-0.2077430405904851" CI_START="-1.792256959409515" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.5" ORDER="160" SD_1="1.2" SD_2="1.4" SE="0.4042201620329438" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2235653496057965" CI_START="-2.823565349605796" DF="0.0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.8157618770858279" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="0.2329993932805685">
<NAME>extrapyramidal (Abnormal Involuntary Movement Scale)</NAME>
<CONT_DATA CI_END="2.2235653496057965" CI_START="-2.823565349605796" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.7" ORDER="161" SD_1="5.1" SD_2="4.0" SE="1.2875570007976462" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5439082608125778" CI_START="-6.343908260812578" DF="0.0" EFFECT_SIZE="-2.9" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.03" NO="3" P_CHI2="1.0" P_Z="0.09885703460265902" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="1.6504201403509693">
<NAME>extrapyramidal (Simpson-Angus Scale)</NAME>
<CONT_DATA CI_END="0.5439082608125778" CI_START="-6.343908260812578" EFFECT_SIZE="-2.9" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="0.4" ORDER="162" SD_1="5.5" SD_2="6.0" SE="1.7571283390805579" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.06196442260233927" CI_END="1.9153221517252073" CI_START="0.10877229678092687" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4564361834019491" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.2822418315421401" LOG_CI_START="-0.9634817010273374" LOG_EFFECT_SIZE="-0.34061993474259866" METHOD="MH" NO="5" P_CHI2="0.8034176079656155" P_Q="0.0" P_Z="0.28379577897531116" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="30" WEIGHT="200.0" Z="1.071831408907968">
<NAME>Adverse events: 2. Discrete events</NAME>
<GROUP_LABEL_1>olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.11928306398171" CI_START="0.022702203963316153" DF="0.0" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.7092091439527669" LOG_CI_START="-1.6439319788137792" LOG_EFFECT_SIZE="-0.46736141743050624" NO="1" P_CHI2="1.0" P_Z="0.43624858757677787" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="0.7785436555971995">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="5.11928306398171" CI_START="0.022702203963316153" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7092091439527669" LOG_CI_START="-1.6439319788137792" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="163" O_E="0.0" SE="1.3822467437494872" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" VAR="1.9106060606060606" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7727296551447718" CI_START="0.094308786328968" DF="0.0" EFFECT_SIZE="0.5113636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.44290752734835154" LOG_CI_START="-1.0254478440980013" LOG_EFFECT_SIZE="-0.29127015837482495" NO="2" P_CHI2="1.0" P_Z="0.4368189630355326" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="15" WEIGHT="100.0" Z="0.7775760981125568">
<NAME>constipation</NAME>
<DICH_DATA CI_END="2.7727296551447718" CI_START="0.094308786328968" EFFECT_SIZE="0.5113636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.44290752734835154" LOG_CI_START="-1.0254478440980013" LOG_EFFECT_SIZE="-0.29127015837482495" ORDER="164" O_E="0.0" SE="0.8625192136639008" STUDY_ID="STD-Tollefson-1997" TOTAL_1="44" TOTAL_2="15" VAR="0.7439393939393939" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>